Hologic (HOLX) 10-Q 31 Jul 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Jun. 28, 2014	Jul. 28, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	28-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Entity Registrant Name	'HOLOGIC INC	'
Entity Central Index Key	'0000859737	'
Current Fiscal Year End Date	'--09-27	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	277,759,686

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Revenues:	'	'	'	'
Product	$529.30	$529.90	$1,562.80	$1,579.30
Service and other	103.3	96.2	307.3	290.9
Revenues	632.6	626.1	1,870.10	1,870.20
Costs of revenues:	'	'	'	'
Product	186.7	187.6	549.3	617.2
Amortization of intangible assets	80.5	76	234.1	227
Impairment of intangible assets	0	1.7	26.6	1.7
Service and other	52.6	51	159.6	153.5
Gross Profit	312.8	309.8	900.5	870.8
Operating expenses:	'	'	'	'
Research and development	52.5	47.8	151.1	148.9
Selling and marketing	83	82.9	245	265.4
General and administrative	64.7	60.5	194.6	179.7
Amortization of intangible assets	29.7	28.7	85	85.9
Impairment of intangible assets	0	0	0.5	0
Contingent consideration – compensation expense	0	21.6	0	80.5
Contingent consideration – fair value adjustments	0	0.5	0	11.3
Gain on sale of intellectual property	0	0	0	-53.9
Restructuring and divestiture charges	6.7	6.7	36.6	23.1
Operating expenses	236.6	248.7	712.8	740.9
Income from operations	76.2	61.1	187.7	129.9
Interest income	0.3	0.3	0.8	0.8
Interest expense	-52.4	-67.2	-168.1	-215.3
Debt extinguishment loss	0	0	-7.4	-3.2
Other expense, net	-1.5	-1.2	-3.5	-0.2
Income (loss) before income taxes	22.6	-7	9.5	-88
Provision (benefit) for income taxes	11.3	4	20.3	-29.1
Net income (loss)	$11.30	($11)	($10.80)	($58.90)
Net income (loss) per common share:	'	'	'	'
Basic (in dollars per share)	$0.04	($0.04)	($0.04)	($0.22)
Diluted (in dollars per share)	$0.04	($0.04)	($0.04)	($0.22)
Weighted average number of shares outstanding:	'	'	'	'
Basic (in shares)	276,843	269,430	274,713	267,983
Diluted (in shares)	279,205	269,430	274,713	267,983

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Loss) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net income (loss)	$11.30	($11)	($10.80)	($58.90)
Changes in foreign currency translation adjustment	3.3	-2.9	-3.7	-9.3
Changes in unrealized holding gains on available-for-sale securities	4.2	0.1	1.9	2.3
Changes in pension plans, net of taxes of $0.2 for the nine months ended June 28, 2014	0	0	-0.6	0
Other comprehensive income (loss)	7.5	-2.8	-2.4	-7
Comprehensive income (loss)	$18.80	($13.80)	($13.20)	($65.90)

Consolidated_Statements_of_Com1

Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Changes in pension plans, tax	$0	$0	$0.20	$0

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 28, 2014	Sep. 28, 2013
In Millions, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$632.50	$822.50
Restricted cash	5.9	6.9
Accounts receivable, less reserves of $11.3 and $8.8, respectively	381.7	409.3
Inventories	329.8	289.4
Deferred income tax assets	34.4	0
Prepaid income taxes	10.3	44.7
Prepaid expenses and other current assets	37.8	48.4
Other current assets – assets held-for-sale	0	3
Total current assets	1,432.40	1,624.20
Property, plant and equipment, net	467.4	491.5
Intangible assets, net	3,558.70	3,906.70
Goodwill	2,811.10	2,814.50
Other assets	142.4	163.9
Total assets	8,412	9,000.80
Current liabilities:	'	'
Current portion of long-term debt	102	563.8
Accounts payable	82.3	80.5
Accrued expenses	266.5	272
Deferred revenue	147.1	132.3
Deferred income tax liabilities	0	39.8
Total current liabilities	597.9	1,088.40
Long-term debt, net of current portion	4,168.50	4,242.10
Deferred income tax liabilities	1,410.80	1,535.30
Deferred service obligations – long-term	21.8	25.5
Other long-term liabilities	181.7	168
Commitments and contingencies (Note 5)	'	'
Stockholders’ equity:	'	'
Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued	0	0
Common stock, $0.01 par value – 750,000 shares authorized; 277,450 and 272,036 shares issued, respectively	2.8	2.7
Additional paid-in-capital	5,639.10	5,536.30
Accumulated deficit	-3,628.70	-3,616.40
Accumulated other comprehensive income	18.1	20.4
Treasury stock, at cost – 219 shares at September 28, 2013	0	-1.5
Total stockholders’ equity	2,031.30	1,941.50
Total liabilities and stockholders’ equity	$8,412	$9,000.80

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 28, 2014	Sep. 28, 2013
In Millions, except Share data in Thousands, unless otherwise specified
Statement of Financial Position [Abstract]	'	'
Accounts receivable, reserves	$11.30	$8.80
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, authorized (in shares)	1,623	1,623
Preferred stock, issued (in shares)	0	0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, authorized (in shares)	750,000	750,000
Common stock, issued (in shares)	277,450	272,036
Treasury stock (in shares)	0	219

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013
OPERATING ACTIVITIES	'	'
Net income (loss)	($10.80)	($58.90)
Adjustments to reconcile net loss to net cash provided by operating activities:	'	'
Depreciation	72.7	70.5
Amortization	319.1	312.9
Non-cash interest expense	52.2	61.2
Stock-based compensation expense	39.1	41.9
Excess tax benefit related to equity awards	-5.2	-5.4
Deferred income taxes	-204.6	-119.4
Gain on sale of intellectual property	0	-53.9
Fair value adjustments to contingent consideration	0	11.3
Fair value write-up of inventory sold	0	52.4
Asset impairment charges	33.3	1.8
Debt extinguishment loss	7.4	3.2
Cost-method equity investment impairment charges	6.9	6.4
Gain on sale of cost-method equity investment	0	-2
Loss on disposal of property and equipment	5.1	3.7
Other	-1.4	2.6
Changes in operating assets and liabilities, net of effects from acquisitions:	'	'
Accounts receivable	28.4	9.3
Inventories	-42.2	12.1
Prepaid income taxes	34.4	37
Prepaid expenses and other assets	13.8	5.3
Accounts payable	1.7	-14.4
Accrued expenses and other liabilities	16.1	32
Deferred revenue	10.7	6.2
Net cash provided by operating activities	376.7	415.8
INVESTING ACTIVITIES	'	'
Acquisition of businesses	0	-6.3
Payment of additional acquisition consideration	0	-16.8
Proceeds from sale of business, net of cash transferred	2.4	86.3
Purchase of property and equipment	-30.9	-41.1
Increase in equipment under customer usage agreements	-26.9	-31.9
Net sales (purchases) of insurance contracts	13.8	-4
Purchases of mutual funds	-29.7	0
Sales of mutual funds	22.4	0
Proceeds from sale of intellectual property	0	60
Purchase of cost-method equity investments	0	-3.6
Sale of a cost-method equity investment	0	2.1
Increase in other assets	-3	-4.6
Net cash (used in) provided by investing activities	-51.9	40.1
FINANCING ACTIVITIES	'	'
Repayment of long-term debt	-578.8	-48.8
Payment of debt issuance costs	-2.4	-7
Payment of contingent consideration	0	-42.4
Payment of deferred acquisition consideration	-5	-1.7
Net proceeds from issuance of common stock pursuant to employee stock plans	75.8	51.2
Excess tax benefit related to equity awards	5.2	5.4
Payment of minimum tax withholdings on net share settlements of equity awards	-9.2	-12
Net cash used in financing activities	-514.4	-55.3
Effect of exchange rate changes on cash and cash equivalents	-0.4	-2.6
Net (decrease) increase in cash and cash equivalents	-190	398
Cash and cash equivalents, beginning of period	822.5	560.4
Cash and cash equivalents, end of period	$632.50	$958.40

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Jun. 28, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The consolidated financial statements of Hologic, Inc. (“Hologic” or the “Company”) presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission (“SEC”) for quarterly reports on Form 10-Q and do not include all of the information and disclosures required by U.S. generally accepted accounting principles (“GAAP”). These financial statements should be read in conjunction with the consolidated financial statements and related notes for the year ended September 28, 2013 included in the Company’s Form 10-K filed with the SEC on November 26, 2013. In the opinion of management, the financial statements and notes contain all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the periods presented.
	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
	The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from management’s estimates if past experience or other assumptions do not turn out to be substantially accurate. Operating results for the three and nine months ended June 28, 2014 are not necessarily indicative of the results to be expected for any other interim period or the entire fiscal year ending September 27, 2014.
	Subsequent Events Consideration
	The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. There were no material recognized subsequent events recorded in the unaudited consolidated financial statements as of and for the three and nine months ended June 28, 2014.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Jun. 28, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	Fair Value Measurements
	Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis
	The Company has an equity investment in a publicly-traded company and mutual funds, both of which are valued using quoted market prices, representing Level 1 assets. The Company has a payment obligation to the participants under its Nonqualified Deferred Compensation Plan (“DCP”). This liability is recorded at fair value based on the underlying value of certain hypothetical investments under the DCP as designated by each participant for their benefit. Since the value of the DCP obligation is based on market prices, the liability is classified within Level 1. In addition, in fiscal 2013, the Company had contingent consideration liabilities related to its acquisitions that were recorded at fair value and were based on Level 3 inputs (see Note 5(a)).
	Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following at June 28, 2014:
					Fair Value at Reporting Date Using
		Balance as of June 28, 2014			Quoted Prices in				Significant				Significant
					Active Market for				Other				Unobservable
					Identical Assets				Observable				Inputs (Level 3)
					(Level 1)				Inputs (Level 2)
	Assets:
	Marketable securities:
	Equity security	$	20		$	20			$	—			$	—
	Mutual funds	18.3			18.3				—				—
	Total	$	38.3		$	38.3			$	—			$	—
	Liabilities:
	Deferred compensation liabilities	$	36		$	36			$	—			$	—
	Contingent consideration	3.1			—				—				3.1
	Total	$	39.1		$	36			$	—			$	3.1
	Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of contingent consideration liabilities, were as follows:
		Three Months Ended							Nine Months Ended
		June 28,			June 29,				June 28,				June 29,
		2014			2013				2014				2013
	Balance at beginning of period	$	3.4		$	3.6			$	3.8			$	86.4
	Contingent consideration recorded at acquisition	—			0.5				—				0.5
	Fair value adjustments	—			0.5				—				11.3
	Payments	(0.3		)	(0.1		)		(0.7		)		(93.7		)
	Balance at end of period	$	3.1		$	4.5			$	3.1			$	4.5
	The contingent consideration liability at June 28, 2014 is related to the Company’s acquisition of Interlace Medical, Inc. (“Interlace”) and represents the remaining amounts withheld from payments made to the former stockholders of Interlace for legal indemnification provisions. As of the end of the second quarter of fiscal 2013, the Interlace contingent liability was no longer being remeasured as the final measurement period lapsed. The withheld amount is being used to pay qualifying legal expenses in connection with the Company's litigation with Smith & Nephew, Inc. (“Smith & Nephew”) (see Note 5(b)).
	Assets Measured and Recorded at Fair Value on a Nonrecurring Basis
	The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets are comprised of cost-method equity investments and long-lived assets, including property, plant and equipment, intangible assets and goodwill.
	In the second quarter of fiscal 2014, the Company evaluated its MRI breast coils product line asset group, which is within its Breast Health segment, for impairment due to the Company’s expectation that it will be sold or disposed of significantly before the end of its previously estimated useful life. The undiscounted cash flows expected to be generated by this asset group over its estimated remaining useful life were not sufficient to recover its carrying value. The Company estimated the fair value of the asset group using market participant assumptions, which were based on underlying cash flow estimates, resulting in an impairment charge of $28.6 million. Pursuant to ASC 360, Property, Plant, and Equipment-Other, subtopic 10-35-28, the impairment charge was allocated to the long-lived assets, with $27.1 million to intangible assets and $1.5 million to property and equipment. The property and equipment charge was recorded to cost of product revenues and general and administrative expenses in the amounts of $0.3 million and $1.2 million, respectively. The estimated fair value of this asset group is subject to change and additional charges may be recorded in the future. The Company believes this adjustment falls within Level 3 of the fair value hierarchy.
	In the first quarter of fiscal 2014, the Company recorded a $3.1 million impairment charge to record certain of its buildings at fair value related to the shutdown of the Hitec organic photoconductor manufacturing line (see Note 3). The Company believes this adjustment falls within Level 3 of the fair value hierarchy.
	The Company holds certain cost-method equity investments in non-publicly traded securities aggregating $5.2 million and $12.6 million at June 28, 2014 and September 28, 2013, respectively, which are included in other long-term assets on the Company’s Consolidated Balance Sheets. These investments are generally carried at cost, less any write-downs for other-than-temporary impairment charges. To determine the fair value of these investments, the Company uses all available financial information related to the entities, including information based on recent or pending third-party equity investments in these entities. In certain instances, a cost method investment’s fair value is not estimated as there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment and to do so would be impractical. For the three and nine month periods ended June 28, 2014, the Company recorded other-than-temporary impairment charges of $3.2 million and $6.9 million, respectively, related to its cost-method equity investments. For the three and nine months ended June 29, 2013, the Company recorded other-than-temporary impairment charges of $4.7 million and $6.4 million, respectively, related to these investments.
	The following chart depicts the level of inputs within the fair value hierarchy used to estimate the fair value of assets measured on a nonrecurring basis for which the Company has recorded impairment charges to date in fiscal 2014:
					Fair Value Measurements Using
		Fair Value			Quoted Prices in			Significant			Significant				Total
					Active Market for			Other			Unobservable				Losses
					Identical Assets			Observable			Inputs (Level 3)
					(Level 1)			Inputs (Level 2)
	Fiscal 2014:
	Intangible assets	$	18.3		—			—			$	18.3			$	(27.1	)
	Property and equipment	1			—			—			1				(1.5		)
	Buildings	1.4			—			—			1.4				(3.1		)
	Cost-method equity investments	0.8			—			—			0.8				(6.9		)
															$	(38.6	)
	Refer to Note 4 for disclosure of the nonrecurring fair value measurement related to the debt extinguishment losses recorded in the second quarter of each of fiscal 2014 and 2013. Refer to Note 13 for the disclosure of the nonrecurring fair value measurement related to the intangible asset impairment charge recorded in the third quarter of fiscal 2013.
	Disclosure of Fair Value of Financial Instruments
	The Company’s financial instruments mainly consist of cash and cash equivalents, accounts receivable, marketable securities, cost-method equity investments, insurance contracts, DCP liability, accounts payable and debt obligations. The carrying amounts of the Company’s cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term nature of these instruments. The Company’s marketable securities are recorded at fair value. The carrying amount of the insurance contracts are recorded at the cash surrender value, as required by U.S. GAAP, which approximates fair value, and the related DCP liability is recorded at fair value. The Company believes the carrying amounts of its cost-method equity investments approximate fair value.
	Amounts outstanding under the Company’s Credit Agreement of $2.06 billion aggregate principal are subject to variable rates of interest based on current market rates, and as such, the Company believes the carrying amount of these obligations approximates fair value. The Company’s Senior Notes had a fair value of approximately $1.06 billion as of June 28, 2014 based on their trading price, representing a Level 1 measurement. The fair value of the Company’s Convertible Notes is based on the trading prices of the respective notes and represents a Level 1 measurement. Refer to Note 4 for the carrying amounts of the various components of the Company’s debt.
	The estimated fair values of the Company’s Convertible Notes at June 28, 2014 were as follows:
	2010 Notes	$	566.4
	2012 Notes	548.6
	2013 Notes	408.9
		$	1,523.90

Restructuring_and_Divestiture_

Restructuring and Divestiture Charges	9 Months Ended
	Jun. 28, 2014
Restructuring and Related Activities [Abstract]	'
Restructuring and Divestiture Charges	'
	Restructuring and Divestiture Charges
	The Company evaluates its operations for opportunities to improve operational effectiveness and efficiency, including facility and operations consolidation, and to better align expenses with revenues. As a result of these assessments, the Company has undertaken various restructuring actions which are described below. The following table displays charges taken related to restructuring actions in fiscal 2014, 2013 and 2012 and a rollforward of the charges to the accrued balances as of June 28, 2014:
		Consolidation of Diagnostics Operations			Closure of Indianapolis Facility			Fiscal 2014 Actions			Fiscal 2013 Actions			Other Operating Cost Reductions			Total
	Restructuring and Divestiture Charges
	Fiscal 2012 charges:
	Non-cash impairment charge	$	0.6		$	—		$	—		$	—		$	—		$	0.6
	Purchase orders and other contractual obligations	—			—			—			—			0.3			0.3
	Workforce reductions	14.2			0.9			—			—			0.2			15.3
	Facility closure costs	—			—			—			—			0.4			0.4
	Other	—			0.9			—			—			—			0.9
	Fiscal 2012 restructuring and divestiture charges	$	14.8		$	1.8		$	—		$	—		$	0.9		$	17.5
	Fiscal 2013 charges:
	Workforce reductions	$	14		$	4.8		$	—		$	11.3		$	1.1		$	31.2
	Facility closure costs	—			0.2			—			—			0.4			0.6
	Other	—			0.7			—			—			0.2			0.9
	Fiscal 2013 restructuring charges	$	14		$	5.7		$	—		$	11.3		$	1.7		$	32.7
	Divestiture net charges																0.1
	Fiscal 2013 restructuring and divestiture charges																$	32.8
	Fiscal 2014 charges:
	Workforce reductions	$	2.3		$	0.2		$	21		$	0.9		$	8.3		$	32.7
	Property impairment	—			—			—			—			3.1			3.1
	Facility closure costs	—			0.5			—			—			—			0.5
	Other	—			—			—			—			0.1			0.1
	Fiscal 2014 restructuring charges	$	2.3		$	0.7		$	21		$	0.9		$	11.5		$	36.4
	Divestiture net charges																0.2
	Fiscal 2014 restructuring and divestiture charges																$	36.6
		Consolidation of Diagnostics Operations			Closure of Indianapolis Facility			Fiscal 2014 Actions			Fiscal 2013 Actions			Other Operating Cost Reductions			Total
	Rollforward of Accrued Restructuring
	Fiscal 2012 charges	$	14.8		$	1.8		$	—		$	—		$	0.9		$	17.5
	Non-cash impairment charges	(0.6		)	—			—			—			—			(0.6		)
	Stock-based compensation	(3.5		)	—			—			—			—			(3.5		)
	Severance payments	(2.4		)	—			—			—			(0.2		)	(2.6		)
	Other payments	—			—			—			—			(0.8		)	(0.8		)
	Acquired and other	0.1			—			—			—			0.1			0.2
	Balance as of September 29, 2012	$	8.4		$	1.8		$	—		$	—		$	0		$	10.2
	Fiscal 2013 restructuring charges	$	14		$	5.7		$	—		$	11.3		$	1.7		$	32.7
	Stock-based compensation	(6.3		)	—			—			(1.6		)	—			(7.9		)
	Severance payments	(13.1		)	(3.1		)	—			(4.4		)	(0.9		)	(21.5		)
	Other payments	—			(0.6		)	—			—			(0.6		)	(1.2		)
	Balance as of September 28, 2013	$	3		$	3.8		$	—		$	5.3		$	0.2		$	12.3
	Fiscal 2014 restructuring charges	$	2.3		$	0.7		$	21		$	0.9		$	11.5		$	36.4
	Stock-based compensation	—			—			(6.5		)	—			—			(6.5		)
	Non-cash impairment charges	—			—			—			—			(3.1		)	(3.1		)
	Severance payments	(0.9		)	(4.0		)	(7.7		)	(5.9		)	(5.9		)	(24.4		)
	Other payments	—			(0.4		)	—			—			(0.1		)	(0.5		)
	Balance as of June 28, 2014	$	4.4		$	0.1		$	6.8		$	0.3		$	2.6		$	14.2
	Consolidation of Diagnostics Operations
	In connection with its acquisition of Gen-Probe Incorporated (“Gen-Probe”), the Company implemented restructuring actions to consolidate its Diagnostics operations, including streamlining product development initiatives, reducing overlapping functional areas in sales, marketing and general and administrative functions, and consolidating manufacturing resources, field services and support. As a result, the Company terminated certain employees from Gen-Probe and its legacy diagnostics business in research and development, sales, marketing, and general and administrative functions. The Company recorded severance and benefit charges in fiscal 2012 of $13.3 million related to this action pursuant to ASC 420, Exit or Disposal Cost Obligations (ASC 420). The majority of these employees ceased working in the fourth quarter of fiscal 2012, and their full severance charge was recorded in the fourth quarter of fiscal 2012. In addition, certain of the terminated Gen-Probe employees had unvested stock options, which were accelerated at termination pursuant to the stock options’ original terms. As such, the severance charges in fiscal 2012 include $3.5 million of stock-based compensation expense. In fiscal 2013, the Company recorded $10.8 million of severance charges, including $6.3 million for stock-based compensation. Included in these charges was $9.7 million recorded in the second quarter of fiscal 2013 related to the termination of certain Gen-Probe executives, including Carl Hull, Gen-Probe’s former Chairman, President and Chief Executive Officer. The charge was for the acceleration of certain retention payments and equity awards pursuant to the original terms of the related agreements. The Company recorded $0.3 million and $10.8 million of severance charges in the three and nine months ended June 29, 2013, respectively. No additional charges were recorded in fiscal 2014 under this portion of the action.
	In addition, the Company is in the process of moving its legacy molecular diagnostics operations from Madison, Wisconsin to Gen-Probe’s facilities in San Diego, California. This transfer is expected to be finalized by the end of fiscal 2014 and, as a result, many of the employees in Madison have been terminated. The Company is recording severance and benefit charges pursuant to ASC 420 and estimates the total severance and benefits charges to be approximately $7.1 million, which is being recorded ratably over the estimated service period of the affected employees. The Company recorded $0.6 million and $2.3 million in the three and nine months ended June 28, 2014, respectively, and $0.8 million and $2.6 million in the three and nine months ended June 29, 2013, respectively. In fiscal 2013 and 2012, the Company recorded $3.2 million and $0.9 million, respectively, for severance and benefits related to this portion of the action.
	Closure of Indianapolis Facility
	In the fourth quarter of fiscal 2012, the Company finalized its decision to transfer production of the majority of its interventional breast products, which are included within the Breast Health reporting segment, from its Indianapolis, Indiana facility to its facility in Costa Rica. The transfer was completed in the first quarter of fiscal 2014, and the termination of employees at the Indianapolis location was completed. The Company recorded total severance and benefit charges under this action of $5.9 million pursuant to ASC 420. These charges were recorded ratably over the required service period of the affected employees. The Company recorded severance and benefits charges of $0.2 million in the first quarter of fiscal 2014. The Company recorded severance and benefit charges of $1.4 million and $4.5 million in the three and nine months ended June 29, 2013, respectively. In fiscal 2013 and 2012, the Company recorded $4.8 million and $0.9 million, respectively, for severance and benefits related to this action. In addition, the Company recorded a charge of $0.4 million in the first quarter of fiscal 2014 related to the termination of its Indianapolis lease. The Company also recorded miscellaneous charges of $0.8 million in fiscal 2013 and $0.9 million in fiscal 2012 for amounts owed to the state of Indiana for employment credits. This action is complete and no additional charges will be recorded.
	Fiscal 2014 Actions
	During the first quarter of fiscal 2014, the Company implemented a cost reduction initiative comprised of reducing headcount and evaluating research projects and operating costs. In connection with this plan, the Company terminated certain employees on a worldwide basis. The Company recorded the severance and benefit charges pursuant to ASC 420 and ASC 712, Compensation-Nonretirement Postemployment Benefits (ASC 712), depending on the employee terminated. The Company recorded $6.3 million of severance and benefit charges in the first quarter of fiscal 2014, which included $0.4 million of stock-based compensation.
	On December 6, 2013, Stephen P. MacMillan was appointed as President, Chief Executive Officer and a director of the Company. The employment of John W. Cumming, the Company’s prior President and Chief Executive Officer, terminated upon Mr. MacMillan’s appointment. The Company provided separation benefits to Mr. Cumming pursuant to his employment letter dated July 18, 2013 resulting in a charge of $6.6 million in the first quarter of fiscal 2014, which included $4.4 million of stock-based compensation related to the acceleration of all of Mr. Cumming’s outstanding equity awards in accordance with the existing terms of Mr. Cumming’s share based payment arrangements.
	In the second and third quarters of fiscal 2014, the Company terminated certain executives and employees and recorded severance and benefit charges of $3.0 million and $5.0 million, respectively. These charges were recorded pursuant to ASC 712. The third quarter charge included $1.7 million of stock-based compensation for the modification of the terms of equity awards to certain employees.
	Fiscal 2013 Actions
	During the third quarter of fiscal 2013, the Company implemented a cost reduction initiative comprised of reducing headcount and evaluating research projects and operating costs. In connection with this plan, the Company terminated certain employees on a worldwide basis. The Company primarily recorded severance and benefit charges pursuant to ASC 420, and the total severance and benefits charge related to this plan was $5.4 million. For those employees who continued to be employed beyond the minimum retention period, charges were recorded ratably over the estimated service period of the affected employees. The Company recorded severance and benefit charges of $0.9 million in the nine months ended June 28, 2014. The Company recorded $3.6 million of severance and benefit charges in the third quarter of fiscal 2013 related to this action.
	During the fourth quarter of fiscal 2013, Robert A. Cascella resigned as the Company’s President and Chief Executive Officer and as a member of the Board of Directors of the Company, and effective at the same time, Mr. Cumming was appointed as the Company’s President and Chief Executive Officer. In connection with this management change, additional headcount reductions were implemented. As a result of this action, the Company recorded $6.8 million in the fourth quarter of fiscal 2013 for severance and benefits charges. All employees were notified prior to September 28, 2013 and primarily ceased employment in the fourth quarter of fiscal 2013. The severance and benefit charges were recorded pursuant to ASC 712 for those employees with contractual arrangements and under ASC 420 for the remainder of the affected employees. In addition to the acceleration of stock options pursuant to the stock options’ original terms for certain employees, the Company also modified the terms of equity awards to certain employees resulting in aggregate stock-based compensation charges of $1.4 million recorded in the fourth quarter of fiscal 2013.
	Other Operating Cost Reductions:
	Hitec-Imaging Organic Photoconductor Manufacturing Line Shut-down
	In the fourth quarter of fiscal 2013, in connection with the Company’s cost reduction initiatives, the Company decided to shut-down its Hitec-Imaging organic photoconductor manufacturing line located in Germany. This production line is included within the Breast Health segment. As a result, the Company terminated certain employees, primarily in manufacturing, in fiscal 2014. During the first quarter of fiscal 2014, the Company completed its negotiations with the local Works Council to determine severance benefits for the approximately 95 affected employees. The Company is recording severance and benefit charges pursuant to ASC 420 and estimates the severance and related charges will be approximately $9.2 million. The Company recorded charges of $7.3 million and $1.1 million in the second and third quarters of fiscal 2014, respectively, in connection with terminating these employees. Additional charges will be recorded in fiscal 2014 and 2015 based on the terms of the benefit arrangements with certain employees.
	In the first quarter of fiscal 2014, the Company recorded an impairment charge of $3.1 million to record certain buildings at this location to their estimated fair value.
	Consolidation of Selenium Panel Coating Production
During the third quarter of fiscal 2012, the Company finalized its decision to consolidate its Selenium panel coating process and transfer the production line to its Newark, Delaware facility from its Hitec-Imaging German subsidiary. This production line is included within the Breast Health segment. The transfer was completed in the fourth quarter of fiscal 2013. In connection with this consolidation plan, the Company terminated certain employees, primarily manufacturing personnel. Severance charges were recorded pursuant to ASC 420. The termination communications began in January 2013 and the Company recorded severance charges of $0.4 million and $1.0 million in the three and nine months ended June 29, 2013, respectively. In connection with this action, the Company recorded severance charges of $1.1 million in fiscal 2013.
Divestitures
In the fourth quarter of fiscal 2013, the Company designated the assets of its Elucigene product line as assets held-for-sale, and recorded a charge of $0.7 million to record the assets at fair value. In the first quarter of fiscal 2014, the Company finalized the sale of the assets for $2.8 million, resulting in additional charges of $0.2 million for the nine months ended June 28, 2014. At September 28, 2013, assets held-for-sale consisted of inventory and certain equipment valued at $2.4 million and goodwill of $0.6 million.The Company completed the sale of its Lifecodes business and recorded a net gain of $0.9 million in the second quarter of fiscal 2013. For the year ended September 28, 2013, the Company recorded a charge of $0.3 million related to the disposition of certain other assets held-for-sale.

Borrowings_and_Credit_Arrangem

Borrowings and Credit Arrangements	9 Months Ended
	Jun. 28, 2014
Debt Disclosure [Abstract]	'
Borrowings and Credit Arrangements	'
	Borrowings and Credit Arrangements
	The Company’s borrowings consisted of the following:
		June 28,		September 28,
		2014		2013
	Current debt obligations, net of debt discount:
	Term Loan A	$	87.1	$	49.7
	Term Loan B	14.9		114
	Convertible Notes	—		400.1
	Total current debt obligations	102		563.8
	Long-term debt obligations, net of debt discount:
	Term Loan A	821.2		894.8
	Term Loan B	1,124.30		1,159.30
	Senior Notes	1,000.00		1,000.00
	Convertible Notes	1,223.00		1,188.00
	Total long-term debt obligations	4,168.50		4,242.10
	Total debt obligations	$	4,270.50	$	4,805.90
	Credit Agreement
	On October 31, 2013, the Company voluntarily pre-paid $100.0 million of its Term Loan B facility, which was reflected in current debt obligations as of September 28, 2013. Pursuant to ASC 470, Debt (ASC 470), the Company recorded a debt extinguishment loss of $2.9 million in the first quarter of fiscal 2014 to write-off the pro-rata amount of unamortized debt discount and deferred issuance costs related to this voluntary prepayment.
	On February 26, 2014, the Company, the Guarantors, Goldman Sachs, and the Lenders entered into Refinancing Amendment No. 3 to the credit and guaranty agreement among the parties (as amended, the “Credit Agreement”). The Refinancing Amendment No. 3 refinanced the Company’s existing senior secured tranche B term loan facility (the “Existing Term Loan B”) with a new senior secured tranche B term loan facility (the “New Term Loan B”) with an issue price of 99.875% of the principal amount of the Existing Term Loan B (subject also to the prepayment referenced below). This amendment resulted in a 50 basis point reduction in the interest rate on the New Term Loan B. Amounts outstanding under the New Term Loan B bear interest, at the Company’s option: (a) at the Base Rate, with a floor of 1.75%, plus 1.50% per annum, or (b) at the Adjusted Eurodollar Rate (i.e., the Libor rate), with a floor of 0.75%, plus 2.50% per annum. In addition, the Company voluntarily prepaid $25.0 million of the New Term Loan B.
	Pursuant to ASC 470, the accounting for this refinancing is required to be evaluated on a creditor-by-creditor basis to determine whether each transaction should be accounted for as a modification or extinguishment. Certain creditors under the Credit Agreement did not participate in this refinancing transaction and ceased being creditors of the Company, and certain creditors reduced their positions. As a result, the Company recorded a debt extinguishment loss of $4.4 million in the second quarter of fiscal 2014 to write-off the pro-rata amount of unamortized debt discount and deferred issuance costs related to these creditors. For the remainder of the creditors, this transaction has been accounted for as a modification because the present value of the cash flows on a creditor-by-creditor basis between the two debt instruments was less than 10%. Pursuant to ASC 470, subtopic 50-40, third-party costs of $1.0 million related to this transaction were expensed.
	Borrowings outstanding under the Credit Agreement for the three and nine months ended June 28, 2014 had weighted-average interest rates of 2.76% and 2.93%, respectively. The interest rates on the outstanding Term Loan A and Term Loan B borrowings at June 28, 2014 were 2.15% and 3.25%, respectively. Interest expense under the Credit Agreement totaled $17.9 million and $57.5 million for the three and nine months ended June 28, 2014, respectively, which includes non-cash interest expense of $3.1 million and $9.6 million, respectively, related to the amortization of the deferred financing costs and accretion of the debt discount. Interest expense totaled $26.1 million and $84.7 million for the three and nine months ended June 29, 2013, respectively, which includes non-cash interest expense of $3.4 million and $11.2 million related to the amortization of the deferred financing costs and accretion of the debt discount.
	In the second quarter of fiscal 2013, the Company executed Refinancing Amendment No. 1 to the Credit Agreement which reduced the interest rate on the Term Loan A facility. Consistent with the accounting treatment noted above for Refinancing Amendment No. 3, in connection with this transaction, the Company recorded a debt extinguishment loss of $3.2 million and expensed $2.4 million of third-party costs to interest expense.
	Senior Notes
	The Company’s 6.25% senior notes due 2020 (the “Senior Notes”) mature on August 1, 2020 and bear interest at the rate of 6.25% per year, payable semi-annually on February 1 and August 1 of each year, commencing on February 1, 2013. The Company recorded interest expense of $16.0 million and $48.0 million in both the three and nine month periods ended June 28, 2014 and June 29, 2013, respectively, which includes non-cash interest expense of $0.4 million and $1.2 million in both the three and nine month periods ended June 28, 2014 and June 29, 2013, respectively, related to the amortization of the deferred financing costs.
	Convertible Notes
	On November 14, 2013, the Company announced that it had issued a notice of redemption to the holders of its 2.00% Convertible Senior Notes due 2037 (“2007 Notes”) to redeem any 2007 Notes outstanding on December 18, 2013 at a redemption price payable in cash equal to 100.00% of the principal amount of the 2007 Notes plus accrued and unpaid interest to, but not including, December 18, 2013. Holders of the 2007 Notes also had the option of putting the 2007 Notes to the Company as of December 13, 2013. The 2007 Notes were redeemed at their par value aggregating $405.0 million. Under ASC 470, the derecognition of the 2007 Notes did not result in a gain or loss as the fair value of the liability component of the 2007 Notes was determined to be equal to the consideration paid to redeem the 2007 Notes, and as a result, no value was allocated to the reacquisition of the conversion option.
	Interest expense under the Convertible Notes is as follows:
		Three Months Ended				Nine Months Ended
		June 28,		June 29,		June 28,		June 29,
		2014		2013		2014		2013
	Amortization of debt discount	$	8.5	$	11.6	$	28.4	$	40.9
	Amortization of deferred financing costs	0.4		0.7		1.5		2.4
	Principal accretion	3.9		3.7		11.4		5.5
	Non-cash interest expense	12.8		16		41.3		48.8
	2.00% accrued interest	4.7		8.6		17.6		25.8
		$	17.5	$	24.6	$	58.9	$	74.6

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Jun. 28, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	(a) Contingent Earn-Out Payments
	In connection with certain of its acquisitions, the Company incurred obligations to make contingent earn-out payments tied to performance criteria, principally revenue growth of the acquired businesses over a specified period.
	In the first quarter of fiscal 2013, the Company made its final contingent consideration payment of $16.8 million to the former shareholders of Adiana, Inc., which was net of amounts withheld for qualifying legal costs, and its final contingent consideration payment of $3.4 million to the former shareholders of Sentinelle Medical Inc.
	In connection with the Company’s acquisition of Interlace in fiscal 2011, the Company had an obligation to the former Interlace stockholders to make contingent payments over a two-year period. Pursuant to ASC 805, Business Combinations, the Company recorded its estimate of the fair value of the contingent consideration liability based on future revenue projections of the Interlace business. The final measurement period ended during the second quarter of fiscal 2013, resulting in a contingent consideration liability of $93.8 million. Of this amount, $86.9 million was paid to the former Interlace stockholders in the second quarter of fiscal 2013. The remainder was withheld for legal indemnification provisions and is being used to pay qualifying legal expenses. At June 28, 2014, the Company had accrued $3.1 million.
	In connection with the Company’s acquisition of TCT International Co., Ltd. (“TCT”) in June 2011, the Company had an obligation to certain of the former TCT shareholders, based on future employment, to make contingent payments over a two year period provided certain revenue milestones were met. These earnouts were recorded as compensation expense ratably over the required service periods. The second and final earn-out period was completed in the third quarter of fiscal 2013, and the Company paid $87.4 million of this earn-out in the fourth quarter of fiscal 2013. The remaining $31.1 million of this earn-out was paid in the first quarter of fiscal 2014.
	There was no contingent consideration expense recorded in the first nine months of fiscal 2014. A summary of amounts recorded to the Consolidated Statements of Operations is as follows:
	Statement of Operations Line Item – 3 Months Ended June 29, 2013	Interlace		TCT		Total
	Contingent consideration – compensation expense	$	—	$	21.6	$	21.6
	Contingent consideration – fair value adjustments	0.5		—		0.5
		$	0.5	$	21.6	$	22.1
	Statement of Operations Line Item – 9 Months Ended June 29, 2013	Interlace		TCT		Total
	Contingent consideration – compensation expense	$	—	$	80.5	$	80.5
	Contingent consideration – fair value adjustments	11.3		—		11.3
		$	11.3	$	80.5	$	91.8
	(b) Litigation and Related Matters
	On June 9, 2010, Smith & Nephew filed suit against Interlace, which the Company acquired on January 6, 2011, in the United States District Court for the District of Massachusetts. The complaint alleged that the Interlace MyoSure hysteroscopic tissue removal device infringed U.S. patent 7,226,459. On November 22, 2011, Smith & Nephew filed suit against the Company in the United States District Court for the District of Massachusetts. The complaint alleged that use of the MyoSure hysteroscopic tissue removal system infringed U.S. patent 8,061,359. Both complaints sought permanent injunctive relief and unspecified damages. On September 4, 2012, following a two week trial, the jury returned a verdict of infringement of both the ‘459 and ‘359 patents and assessed damages of $4.0 million. A bench trial regarding the Company’s assertion of inequitable conduct on the part of Smith & Nephew with regard to the ‘359 patent was held on December 9, 2012 and oral arguments on the issue of inequitable conduct were presented on February 27, 2013. On June 27, 2013, the Court denied the Company’s motions related to inequitable conduct and allowed Smith & Nephew’s request for injunction, but ordered that enforcement of the injunction be stayed until final resolution, including appeal, of the current re-examinations of both patents at the United States Patent and Trademark Office (“USPTO”). The Court also rejected the jury’s damage award and ordered the parties to identify a mechanism for resolving the damages issue. On September 12, 2013, a status conference was held, and the Court invited the parties to submit briefs on the relevance of recent activity in the re-examinations at the USPTO. A hearing on this topic was held on October 29, 2013, and the parties are awaiting the Court’s ruling. The Company intends to file post-trial motions seeking to reverse the jury’s verdict. On January 14, 2014, the USPTO issued a final decision that the claims of the ‘459 patent asserted as part of the litigation are not patentable. On February 13, 2014, Smith & Nephew appealed this decision to the U.S. Patent Trial and Appeal Board. The re-examination of the ‘359 patent is on-going. It is expected that patentability decisions made by the USPTO for both patents will proceed to appeal. At this time, based on available information regarding this litigation, the Company is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses.
	On March 6, 2012, Enzo Life Sciences, Inc. (“Enzo”) filed suit against the Company in the United States District Court for the District of Delaware. The complaint alleged that certain of the Company’s molecular diagnostics products, including without limitation products based on its proprietary Invader chemistry, such as Cervista HPV HR and Cervista HPV 16/18, infringe Enzo’s U.S. patent 6,992,180. The complaint seeks permanent injunctive relief and unspecified damages. The Company was formally served with the complaint on July 3, 2012, and a trial is tentatively scheduled for the fall of 2015. In January 2012, Enzo filed suit against Gen-Probe in the United States District Court for the District of Delaware. The Gen-Probe complaint alleged that certain of Gen-Probe’s diagnostics products, including products that incorporate Gen-Probe’s patented hybridization protection assay technology, such as the Aptima Combo 2 and Aptima HPV assays, infringe Enzo’s U.S. patent 6,992,180. On September 30, 2013, Enzo amended its list of accused products to include Prodesse, MilliPROBE, PACE and Procleix assays. The complaint seeks permanent injunctive relief and unspecified damages. Enzo has asserted the ‘180 patent claims against six other companies. The defendant companies are jointly arguing issues related to claim construction, and the trials are tentatively scheduled to begin in the fall of 2015. At this time, based on available information regarding this litigation, the Company is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses.
	On October 29, 2013, the Interlace stockholder representatives filed a complaint in the Delaware Court of Chancery alleging breach of contract for issues related to the payment of contingent consideration under the Interlace acquisition agreement, and are seeking $14.7 million in additional payments. The Company believes that Interlace has been paid all amounts due under the acquisition agreement and that the claims are without merit. The Company is currently undergoing discovery. At this time, the Company is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or range of estimates, of potential losses.
	The Company is a party to various other legal proceedings and claims arising out of the ordinary course of its business. The Company believes that except for those described above there are no other proceedings or claims pending against it of which the ultimate resolution would have a material adverse effect on its financial condition or results of operations. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal costs are expensed as incurred.

Sale_of_Makena

Sale of Makena	9 Months Ended
	Jun. 28, 2014
Regulatory Assets [Abstract]	'
Sale of Makena	'
	Sale of Makena
	In fiscal 2008, the Company sold the rights of its Makena (formerly Gestiva) pharmaceutical product to K-V Pharmaceutical Company (“KV”) upon FDA approval of the then pending Makena new drug application. The Company executed certain amendments to this agreement that resulted in an increase in the total sales price to $199.5 million and a change in the timing of when payments were due to the Company. On February 3, 2011, the Company received FDA approval of Makena, and all rights to Makena were transferred to KV. The Company had received scheduled payments as required under the agreement until August 2012 when KV and certain of its subsidiaries filed voluntary petitions for reorganization under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court. At that time, additional payments were still owed to the Company, and in December 2012 the Company and KV executed a settlement agreement, which released KV from all claims in consideration of a $60.0 million payment. The Company recorded this amount in the first quarter of fiscal 2013, net of certain costs, resulting in a gain of $53.9 million. The Company will receive no further payments from KV.

Marketable_Securities

Marketable Securities	9 Months Ended
	Jun. 28, 2014
Investments, Debt and Equity Securities [Abstract]	'
Marketable Securities	'
	Marketable Securities
	The following reconciles the cost basis to the fair market value of the Company’s equity security that is classified as available-for-sale:
	Period Ended:	Cost		Gross Unrealized		Gross Unrealized		Fair Value
				Gains		Losses
	28-Jun-14	$	5.9	$	14.1	$	—	$	20
	28-Sep-13	$	5.9	$	12.2	$	—	$	18.1

Net_Income_Loss_Per_Share

Net Income (Loss) Per Share	9 Months Ended
	Jun. 28, 2014
Earnings Per Share [Abstract]	'
Net Loss Per Share	'
	Net Income (Loss) Per Share
	A reconciliation of basic and diluted share amounts is as follows:
		Three Months Ended		Nine Months Ended
		June 28,	June 29,	June 28,	June 29,
		2014	2013	2014	2013
	Basic weighted average common shares outstanding	276,843	269,430	274,713	267,983
	Weighted average common stock equivalents from assumed exercise of stock options and restricted stock units	2,130	—	—	—
	Incremental shares from assumed conversion of the Convertible Notes premium	232	—	—	—
	Diluted weighted average common shares outstanding	279,205	269,430	274,713	267,983
	Weighted-average anti-dilutive shares related to:
	Outstanding stock options	4,727	7,964	7,007	8,724
	Restricted stock units	21	1,147	811	1,089
	As more fully discussed in Note 4, the Company has outstanding Convertible Notes. The Company’s policy is to net share settle its Convertible Notes, and any conversion premium, at the Company’s option, may be satisfied by issuing shares of common stock, cash or a combination of shares and cash. As such, dilution related to the conversion premium on the 2010 Notes is included in the calculation of diluted weighted-average shares outstanding. Except for the three months ended June 28, 2014, shares potentially issuable for the conversion premium of the Convertible Notes were excluded from the calculation of earnings per share as their effect would have been anti-dilutive.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Jun. 28, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation	'
	Stock-Based Compensation
	The following presents stock-based compensation expense in the Company’s Consolidated Statements of Operations:
		Three Months Ended						Nine Months Ended
		June 28,			June 29,			June 28,			June 29,
		2014			2013			2014			2013
	Cost of revenues	$	1.9		$	1.7		$	5.5		$	5.2
	Research and development	2.2			1.7			6.3			5.6
	Selling and marketing	2			2.2			6.1			7
	General and administrative	5.2			4.7			14.7			16.4
	Restructuring and divestiture	1.7			0.5			6.5			7.7
		$	13		$	10.8		$	39.1		$	41.9
	The Company granted approximately 2.4 million and 2.3 million stock options during the nine months ended June 28, 2014 and June 29, 2013, respectively, with weighted-average exercise prices of $21.92 and $19.95, respectively. There were 9.9 million options outstanding at June 28, 2014 with a weighted-average exercise price of $20.31.
	The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table:
		Three Months Ended						Nine Months Ended
		June 28,			June 29,			June 28,			June 29,
		2014			2013			2014			2013
	Risk-free interest rate	1.3		%	0.5		%	1.2		%	0.5		%
	Expected volatility	41.4		%	43.7		%	41.4		%	43.7		%
	Expected life (in years)	4.5			4.4			4.4			4.4
	Dividend yield	—			—			—			—
	Weighted average fair value of options granted	$	7.97		$	7.47		$	7.64		$	7.09
	The Company granted approximately 2.4 million and 2.0 million restricted stock units (RSUs) during the nine months ended June 28, 2014 and June 29, 2013, respectively, with weighted-average grant date fair values of $21.97 and $19.86, respectively. As of June 28, 2014, there were 4.2 million unvested RSUs outstanding with a weighted-average grant date fair value of $20.61. The Company granted approximately 0.4 million performance stock units (PSUs) in the first quarter of fiscal 2014 to members of its senior management team, which have a weighted-average grant date fair value of $21.77. Each recipient of the PSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of three years provided the Company’s defined Return on Invested Capital metrics are achieved. The Company is recognizing compensation expense ratably over the required service period based on its estimate that it is probable the targeted number of shares will vest. If there is a change in the estimate of the number of shares that are probable of vesting, the Company will cumulatively adjust compensation expense in the period that the change in estimate is made.
	In connection with appointing its new President and Chief Executive Officer in December 2013, the Company granted approximately 0.1 million market stock units (MSUs). The MSUs vest in three separate tranches in an amount of 1/3rd of the total amount of the award based on the Company’s stock price meeting certain defined average stock prices for 30 consecutive trading days. These MSUs were valued at an average of $18.65 using the Monte Carlo simulation model and each tranche has its own derived service period. The Company is recognizing compensation expense under the accelerated method as prescribed by ASC 718, Compensation-Stock Compensation (ASC 718). In addition, per the terms of his employment agreement, the Company granted 0.2 million RSUs to match Mr. MacMillan’s purchase of 0.2 million shares of the Company’s common stock on the open market in the second quarter of fiscal 2014. The RSUs cliff vest three years from the date of grant, and the Company is accounting for this grant as a liability award pursuant to ASC 718 because this RSU award contains an additional vesting condition (the requirement that Mr. MacMillan retain the matching shares during the vesting period) that is not service, performance or market based.
	At June 28, 2014, there was $26.9 million and $72.8 million of unrecognized compensation expense related to stock options and stock units (comprised of RSUs, MSUs and PSUs), respectively, to be recognized over a weighted-average period of 3.1 years and 2.8 years, respectively.

Other_Balance_Sheet_Informatio

Other Balance Sheet Information	9 Months Ended
	Jun. 28, 2014
Other Balance Sheet Information [Abstract]	'
Other Balance Sheet Information	'
	Other Balance Sheet Information
		June 28,			September 28,
		2014			2013
	Inventories
	Raw materials	$	121		$	115.6
	Work-in-process	59			51.2
	Finished goods	149.8			122.6
		$	329.8		$	289.4
	Property, plant and equipment
	Equipment and software	$	341.6		$	318.5
	Equipment under customer usage agreements	285.3			275.7
	Building and improvements	175.6			171.5
	Leasehold improvements	64.1			68.2
	Land	51.7			51.6
	Furniture and fixtures	16.3			22.5
		934.6			908
	Less – accumulated depreciation and amortization	(467.2		)	(416.5		)
		$	467.4		$	491.5

Business_Segments_and_Geograph

Business Segments and Geographic Information	9 Months Ended
	Jun. 28, 2014
Segment Reporting [Abstract]	'
Business Segments and Geographic Information	'
	Business Segments and Geographic Information
	The Company has four reportable segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Certain reportable segments represent an aggregation of operating units within each segment. The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges, such as intangible asset amortization expense, intangible asset and goodwill impairment charges, contingent consideration charges, acquisition related fair value adjustments and integration expenses, restructuring and divestiture charges and other one-time or unusual items and related tax effects.
	Identifiable assets for the four principal operating segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its four reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no intersegment revenues during the three and nine months ended June 28, 2014 and June 29, 2013. Segment information is as follows:
		Three Months Ended							Nine Months Ended
		June 28,			June 29,				June 28,			June 29,
		2014			2013				2014			2013
	Total revenues:
	Diagnostics	$	293.1		$	297.4			$	869.7		$	899.8
	Breast Health	238			230				703.2			671
	GYN Surgical	78.5			75.8				229.4			230.4
	Skeletal Health	23			22.9				67.8			69
		$	632.6		$	626.1			$	1,870.10		$	1,870.20
	Operating income (loss):
	Diagnostics	$	4.8		$	(1.2	)		$	24.8		$	(33.7	)
	Breast Health	58.4			53.2				128			146
	GYN Surgical	9.1			6.3				26.8			9.1
	Skeletal Health	3.9			2.8				8.1			8.5
		$	76.2		$	61.1			$	187.7		$	129.9
	Depreciation and amortization:
	Diagnostics	$	95.8		$	92.2			$	282.6		$	273.2
	Breast Health	11.7			10				30.2			30.1
	GYN Surgical	26.3			26.5				78.4			79.5
	Skeletal Health	0.2			0.2				0.6			0.6
		$	134		$	128.9			$	391.8		$	383.4
	Capital expenditures:
	Diagnostics	$	12.8		$	13.4			$	37.9		$	40.6
	Breast Health	2.7			4.2				6.8			13.7
	GYN Surgical	2			2.4				5.9			7.4
	Skeletal Health	—			0.2				0.2			0.4
	Corporate	2.5			6				7			10.9
		$	20		$	26.2			$	57.8		$	73
		June 28,			September 28,
		2014			2013
	Identifiable assets:
	Diagnostics	$	4,468.60		$	4,667.90
	Breast Health	882.8			932.2
	GYN Surgical	1,770.90			1,849.50
	Skeletal Health	25.5			33.5
	Corporate	1,264.20			1,517.70
		$	8,412.00		$	9,000.80
	The Company had no customers with balances greater than 10% of accounts receivable as of June 28, 2014 or September 28, 2013, or any customer that represented greater than 10% of consolidated revenues during the three and nine months ended June 28, 2014 and June 29, 2013.
	The Company operates in the following major geographic areas as noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from France, Germany and the United Kingdom. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “All others” designation includes Canada, Latin America and the Middle East.
	Revenues by geography as a percentage of total revenues were as follows:
		Three Months Ended					Nine Months Ended
		June 28,		June 29,			June 28,			June 29,
		2014		2013			2014			2013
	United States	76	%	75	%		75	%		74	%
	Europe	12	%	13	%		14	%		14	%
	Asia-Pacific	8	%	8	%		7	%		8	%
	All others	4	%	4	%		4	%		4	%
		100	%	100	%		100	%		100	%

Income_Taxes

Income Taxes	9 Months Ended
	Jun. 28, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	In accordance with ASC 740, Income Taxes (ASC 740), each interim period is considered integral to the annual period, and tax expense is measured using an estimated annual effective tax rate. An entity is required to record income tax expense each quarter based on its annual effective tax rate estimated for the full fiscal year and use that rate to provide for income taxes on a current year-to-date basis, adjusted for discrete taxable events that occur during the interim period. If, however, the entity is unable to reliably estimate its annual effective tax rate, then the actual effective tax rate for the year-to-date may be the best annual effective tax rate estimate. For the nine months ended June 29, 2013, the Company determined that it was unable to make a reliable annual effective tax rate estimate due to the rate sensitivity as it related to its forecasted fiscal 2013 results. Therefore, the Company recorded a tax benefit for the nine months ended June 29, 2013 based on the effective rate for the nine months ended June 29, 2013.
	The Company’s effective tax rate for the three and nine month periods ended June 28, 2014 was 50.0% and 214.2%, respectively, compared to a provision of 58.2% and a benefit of 33.0%, respectively, on pre-tax losses for the corresponding periods in the prior year. For the current three and nine month periods, the effective tax rate differed from the statutory rate primarily due to unbenefited foreign losses. For the three months ended June 29, 2013, the tax rate was higher than the statutory rate primarily due to non-deductible contingent consideration expense related to the TCT acquisition and unbenefited foreign losses, partially offset by the domestic production activities deduction. For the nine months ended June 29, 2013, the tax rate was lower than the statutory rate primarily due to a $19.6 million valuation allowance release related to capital losses which were utilized to offset capital gains generated during the year, partially offset by non-deductible contingent consideration expense related to the TCT and Interlace acquisitions and unbenefited losses.

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	9 Months Ended
	Jun. 28, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets	'
	Goodwill and Intangible Assets
	Goodwill
	A rollforward of goodwill activity by reportable segment from September 28, 2013 to June 28, 2014 is as follows:
		Diagnostics			Breast Health			GYN Surgical			Skeletal Health		Total
	Balance at September 28, 2013	$	1,153.50		$	636.4		$	1,016.40		$	8.2	$	2,814.50
	Disposition of a portion of a reporting unit	(0.2		)	—			—			—		(0.2		)
	Tax adjustments	(0.6		)	—			—			—		(0.6		)
	Foreign currency and other	(0.6		)	(1.7		)	(0.3		)	—		(2.6		)
	Balance at June 28, 2014	$	1,152.10		$	634.7		$	1,016.10		$	8.2	$	2,811.10
	Intangible Assets
	Intangible assets consisted of the following:
	Description	As of June 28, 2014						As of September 28, 2013
		Gross			Accumulated			Gross			Accumulated
		Carrying			Amortization			Carrying			Amortization
		Value						Value
	Developed technology	$	3,969.90		$	1,317.60		$	4,009.00		$	1,094.50
	In-process research and development	23			—			24			—
	Customer relationships and contracts	1,101.90			362.5			1,101.90			296.5
	Trade names	236.8			98.8			238.1			81.8
	Patents	14.1			8.8			13			8.5
	Business licenses	2.6			1.9			2.6			0.6
		$	5,348.30		$	1,789.60		$	5,388.60		$	1,481.90
	The Company recorded impairment charges of $26.6 million and $0.5 million to developed technology and trade names, respectively, in the second quarter of fiscal 2014. In addition, the Company periodically re-evaluates the lives of its definite-lived intangible assets, and in the second quarter of fiscal 2014 shortened the life of certain corporate trade names, which will be phased out. Additionally, in the third quarter of fiscal 2014, the Company shortened the life of certain intangible assets associated with the MRI breast coils product line.
	During the third quarter of fiscal 2013, the Company determined that a developed technology asset was impaired and recorded a $1.7 million charge to cost of product revenues to record the asset at its estimated fair value.
	The estimated remaining amortization expense as of June 28, 2014 for each of the five succeeding fiscal years is as follows:
	Remainder of Fiscal 2014	$	109.5
	Fiscal 2015	$	414.6
	Fiscal 2016	$	374.5
	Fiscal 2017	$	365.4
	Fiscal 2018	$	354.9

Product_Warranties

Product Warranties	9 Months Ended
	Jun. 28, 2014
Guarantees [Abstract]	'
Product Warranties	'
	Product Warranties
	Product warranty activity was as follows:
		Balance at		Provisions		Settlements/			Balance at
		Beginning of				Adjustments			End of Period
		Period
	Nine Months Ended:
	28-Jun-14	$	9.3	$	5.5	$	(7.5	)	$	7.3
	29-Jun-13	$	6.2	$	8.8	$	(7.2	)	$	7.8

Stockholders_Rights_Plan_Notes

Stockholders Rights Plan (Notes)	9 Months Ended
	Jun. 28, 2014
Stockholder Rights Plan [Abstract]	'
Stockholder Rights Plan	'
	Stockholder Rights Plan
	On June 24, 2014, the Company entered into Amendment No. 1 (the “Amendment”) to the Rights Agreement (the “Rights Agreement”), dated as of November 21, 2013, by and between the Company and American Stock Transfer & Trust Company, LLC, as rights agent. The Amendment accelerated the expiration of the Company’s preferred share purchase rights (the “Rights”) from November 20, 2014 to June 24, 2014, and had the effect of terminating the Rights Agreement on that date. At the time of the termination of the Rights Agreement, all of the Rights distributed to holders of the Company’s common stock pursuant to the Rights Agreement expired.

New_Accounting_Pronouncements

New Accounting Pronouncements	9 Months Ended
	Jun. 28, 2014
Accounting Changes and Error Corrections [Abstract]	'
New Accounting Pronouncements	'
	New Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 660), which provides guidance for revenue recognition. This ASU is applicable to any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 will supersede the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled to receive in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under current US GAAP. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation.  ASU 2014-09 is effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2016, which is fiscal 2018 for the Company. The Company is currently evaluating the impact of the adoption of ASU 2014-09 on its consolidated financial position and results of operations.
	In April 2014, the FASB issued ASU 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, which amends the guidance for reporting discontinued operations and disposals of components of an entity. The amended guidance requires that a disposal representing a strategic shift in operations, such as a disposal of a major line of business or geographic area, that has (or will have) a major effect on an entity’s financial results should be reported as discontinued operations. ASU 2014-08 also expands the disclosure requirements for discontinued operations and adds new disclosures for individually significant dispositions that do not qualify as discontinued operations. ASU 2014-08 is effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2014 (early adoption is permitted only for disposals that have not been previously reported). The implementation of ASU 2014-08 is not expected to have a material impact on the Company’s consolidated financial position or results of operations.
	In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exist. ASU 2013-11 amends the presentation requirements of ASC 740 and requires an unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, similar tax loss, or a tax credit carryforward. To the extent the tax benefit is not available at the reporting date under the governing tax law or if the entity does not intend to use the deferred tax asset for such purpose, the unrecognized tax benefit should be presented as a liability and not combined with deferred tax assets. The ASU is effective for annual periods, and interim periods within those years, beginning after December 15, 2013, which is fiscal 2015 for the Company. The amendments are to be applied to all unrecognized tax benefits that exist as of the effective date and may be applied retrospectively to each prior reporting period presented. The Company is currently evaluating the impact of the adoption of ASU 2013-11 on its consolidated financial position or results of operations.

Supplemental_Guarantor_Condens

Supplemental Guarantor Condensed Consolidating Financials	9 Months Ended
	Jun. 28, 2014
Condensed Financial Information of Parent Company Only Disclosure [Abstract]	'
Supplemental Guarantor Condensed Consolidating Financials	'
	Supplemental Guarantor Condensed Consolidating Financials
	The Company’s Senior Notes are fully and unconditionally and jointly and severally guaranteed by Hologic, Inc. (“Parent/Issuer”) and certain of its domestic subsidiaries, which are 100% owned by Hologic, Inc. The following represents the supplemental condensed financial information of Hologic, Inc. and its guarantor and non-guarantor subsidiaries, as of June 28, 2014 and September 28, 2013 and for the three and nine months ended June 28, 2014 and June 29, 2013, as applicable.
	SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS
	For the Three Months Ended June 28, 2014
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
	Revenues:
	Product	$	128.4		$	386.4		$	125.8		$	(111.3	)	$	529.3
	Service and other	88.2			14.4			13.1			(12.4		)	103.3
		216.6			400.8			138.9			(123.7		)	632.6
	Costs of revenues:
	Product	61.5			147.3			89.2			(111.3		)	186.7
	Amortization of intangible assets	1.4			75.3			3.8			—			80.5
	Service and other	46.8			5.9			12.3			(12.4		)	52.6
	Gross Profit	106.9			172.3			33.6			—			312.8
	Operating expenses:
	Research and development	7.7			42.9			1.9			—			52.5
	Selling and marketing	16.8			43.4			22.8			—			83
	General and administrative	15.8			37.8			11.1			—			64.7
	Amortization of intangible assets	0.6			26.8			2.3			—			29.7
	Restructuring and divestiture charges	1			2.9			2.8			—			6.7
		41.9			153.8			40.9			—			236.6
	Income (loss) from operations	65			18.5			(7.3		)	—			76.2
	Interest income	0.1			1.1			0.2			(1.1		)	0.3
	Interest expense	(52.6		)	(0.3		)	(0.6		)	1.1			(52.4		)
	Other (expense) income, net	1.3			(3.0		)	0.2			—			(1.5		)
	Income (loss) before income taxes	13.8			16.3			(7.5		)	—			22.6
	Provision for income taxes	6.8			3.6			0.9			—			11.3
	Equity in earnings (losses) of subsidiaries	4.3			3.3			—			(7.6		)	—
	Net income (loss)	$	11.3		$	16		$	(8.4	)	$	(7.6	)	$	11.3
	SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS
	For the Nine Months Ended June 28, 2014
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
	Revenues:
	Product	$	356.8		$	1,154.00		$	373.7		$	(321.7	)	$	1,562.80
	Service and other	262.7			47.4			37.2			(40.0		)	307.3
		619.5			1,201.40			410.9			(361.7		)	1,870.10
	Costs of revenues:
	Product	172.4			431.7			266.9			(321.7		)	549.3
	Amortization of intangible assets	4.2			224			5.9			—			234.1
	Impairment of intangible assets	—			—			26.6			—			26.6
	Service and other	140.3			27.5			31.8			(40.0		)	159.6
	Gross Profit	302.6			518.2			79.7			—			900.5
	Operating expenses:
	Research and development	23			121.7			6.4			—			151.1
	Selling and marketing	52.6			126.8			65.6			—			245
	General and administrative	45.5			114.9			34.2			—			194.6
	Amortization of intangible assets	2.4			77.9			4.7			—			85
	Impairment of intangible assets	—			—			0.5			—			0.5
	Restructuring and divestiture charges	7.6			15			14			—			36.6
		131.1			456.3			125.4			—			712.8
	Income (loss) from operations	171.5			61.9			(45.7		)	—			187.7
	Interest income	0.3			2.3			0.7			(2.5		)	0.8
	Interest expense	(168.0		)	(0.8		)	(1.8		)	2.5			(168.1		)
	Debt extinguishment loss	(7.4		)	—			—			—			(7.4		)
	Other (expense) income, net	7.9			(12.4		)	1			—			(3.5		)
	Income (loss) before income taxes	4.3			51			(45.8		)	—			9.5
	Provision for income taxes	5			9.9			5.4			—			20.3
	Equity in earnings (losses) of subsidiaries	(10.1		)	14.3			—			(4.2		)	—
	Net (loss) income	$	(10.8	)	$	55.4		$	(51.2	)	$	(4.2	)	$	(10.8	)
	SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS
	For the Three Months Ended June 29, 2013
	Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
				Subsidiaries			Subsidiaries
Revenues:
Product	$	106.5		$	399.1		$	114.8		$	(90.5	)	$	529.9
Service and other	81.4			15.9			11.3			(12.4		)	96.2
	187.9			415			126.1			(102.9		)	626.1
Costs of revenues:
Product	57.7			143.8			76.6			(90.5		)	187.6
Amortization of intangible assets	1.3			73.7			1			—			76
Impairment of intangible assets	—			—			1.7			—			1.7
Service and other	39.1			14.8			9.5			(12.4		)	51
Gross profit	89.8			182.7			37.3			—			309.8
Operating expenses:
Research and development	8			37.2			2.6			—			47.8
Selling and marketing	17.9			43.5			21.5			—			82.9
General and administrative	20			31.3			9.2			—			60.5
Amortization of intangible assets	0.8			26.7			1.2			—			28.7
Contingent consideration – compensation expense	21.6			—			—			—			21.6
Contingent consideration – fair value adjustments	0.5			—			—			—			0.5
Restructuring and divestiture charges	0.6			3.7			2.4			—			6.7
	69.4			142.4			36.9			—			248.7
Income from operations	20.4			40.3			0.4			—			61.1
Interest income	0.1			—			0.2			—			0.3
Interest expense	(66.3		)	(0.3		)	(0.6		)	—			(67.2		)
Other (expense) income, net	178.1			(179.2		)	(0.1		)	—			(1.2		)
(Loss) income before income taxes	132.3			(139.2		)	(0.1		)	—			(7.0		)
Provision (benefit) for income taxes	50.9			(49.9		)	3			—			4
Equity in earnings (losses) of subsidiaries	(92.4		)	1.1			—			91.3			—
Net (loss) income	$	(11.0	)	$	(88.2	)	$	(3.1	)	$	91.3		$	(11.0	)
SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS
For the Nine Months Ended June 29, 2013
	Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
				Subsidiaries			Subsidiaries
Revenues:
Product	$	305.2		$	1,177.70		$	365.3		$	(268.9	)	$	1,579.30
Service and other	240.5			56.5			34.6			(40.7		)	290.9
	545.7			1,234.20			399.9			(309.6		)	1,870.20
Costs of revenues:
Product	163.7			478.1			244.3			(268.9		)	617.2
Amortization of intangible assets	4			219.8			3.2			—			227
Impairment of intangible assets	—			—			1.7			—			1.7
Service and other	118.1			46.2			29.9			(40.7		)	153.5
Gross profit	259.9			490.1			120.8			—			870.8
Operating expenses:
Research and development	22.7			118.8			7.4			—			148.9
Selling and marketing	59.1			136.2			70.1			—			265.4
General and administrative	52			101			26.7			—			179.7
Amortization of intangible assets	2.2			80.1			3.6			—			85.9
Contingent consideration – compensation expense	80.5			—			—			—			80.5
Contingent consideration – fair value adjustments	11.3			—			—			—			11.3
Gain on sale of intellectual property	—			(53.9		)	—			—			(53.9		)
Restructuring and divestiture charges	0.9			17.7			4.5			—			23.1
	228.7			399.9			112.3			—			740.9
Income from operations	31.2			90.2			8.5			—			129.9
Interest income	0.4			0.1			0.3			—			0.8
Interest expense	(212.9		)	(0.9		)	(1.5		)	—			(215.3		)
Debt extinguishment loss	(3.2		)	—			—			—			(3.2		)
Other income (expense), net	179.8			(186.3		)	6.3			—			(0.2		)
(Loss) income before income taxes	(4.7		)	(96.9		)	13.6			—			(88.0		)
(Benefit) provision for income taxes	24.3			(61.1		)	7.7			—			(29.1		)
Equity in earnings (losses) of subsidiaries	(29.9		)	14.5			—			15.4			—
Net (loss) income	$	(58.9	)	$	(21.3	)	$	5.9		$	15.4		$	(58.9	)
SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
For the Three Months Ended June 28, 2014
	Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
				Subsidiaries			Subsidiaries
Net income (loss)	$	11.3		$	16		$	(8.4	)	$	(7.6	)	$	11.3
Changes in foreign currency translation adjustment	—			0.3			3			—			3.3
Changes in unrealized holding gain on available-for-sale securities	—			4.2			—			—			4.2
Comprehensive income (loss)	$	11.3		$	20.5		$	(5.4	)	$	(7.6	)	$	18.8
For the Nine Months Ended June 28, 2014
	Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
				Subsidiaries			Subsidiaries
Net (loss) income	$	(10.8	)	$	55.4		$	(51.2	)	$	(4.2	)	$	(10.8	)
Changes in foreign currency translation adjustment	—			0.4			(4.1		)	—			(3.7		)
Changes in unrealized holding gain on available-for-sale securities	—			1.9			—			—			1.9
Changes in pension plans, net of taxes	—			—			(0.6		)	—			(0.6		)
Comprehensive (loss) income	$	(10.8	)	$	57.7		$	(55.9	)	$	(4.2	)	$	(13.2	)
For the Three Months Ended June 29, 2013
	Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
				Subsidiaries			Subsidiaries
Net (loss) income	$	(11.0	)	$	(88.2	)	$	(3.1	)	$	91.3		$	(11.0	)
Changes in foreign currency translation adjustment	—			—			(2.9		)	—			(2.9		)
Changes in unrealized holding gain on available-for-sale securities	—			0.1			—			—			0.1
Comprehensive (loss) income	$	(11.0	)	$	(88.1	)	$	(6.0	)	$	91.3		$	(13.8	)
For the Nine Months Ended June 29, 2013
	Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
				Subsidiaries			Subsidiaries
Net (loss) income	$	(58.9	)	$	(21.3	)	$	5.9		$	15.4		$	(58.9	)
Changes in foreign currency translation adjustment	—			0.2			(9.5		)	—			(9.3		)
Changes in unrealized holding gain on available-for-sale securities	—			2.3			—			—			2.3
Comprehensive (loss) income	$	(58.9	)	$	(18.8	)	$	(3.6	)	$	15.4		$	(65.9	)
SUPPLEMENTAL CONDENSED CONSOLIDATING BALANCE SHEET
June 28, 2014
	Parent/			Guarantor			Non-Guarantor			Eliminations			Consolidated
	Issuer			Subsidiaries			Subsidiaries
ASSETS
Current assets:
Cash and cash equivalents	$	215.4		$	272.6		$	144.5		$	—		$	632.5
Restricted cash	—			—			5.9			—			5.9
Accounts receivable, net	114.3			168.7			98.7			—			381.7
Inventories	88.8			186.1			54.9			—			329.8
Deferred income tax assets	14.4			19.2			0.8			—			34.4
Prepaid income taxes	6			2.9			1.4			—			10.3
Prepaid expenses and other current assets	18.7			10.1			9			—			37.8
Intercompany receivables	—			2,663.60			13.4			(2,677.0		)	—
Total current assets	457.6			3,323.20			328.6			(2,677.0		)	1,432.40
Property, plant and equipment, net	29.2			338			100.2			—			467.4
Intangible assets, net	14.1			3,484.20			60.4			—			3,558.70
Goodwill	282.4			2,391.00			137.7			—			2,811.10
Other assets	92.1			48.5			1.8			—			142.4
Long term intercompany receivables	—			144			—			(144.0		)	—
Investment in subsidiaries	8,681.00			220.3			0.2			(8,901.5		)	—
Total assets	$	9,556.40		$	9,949.20		$	628.9		$	(11,722.5	)	$	8,412.00
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current portion of long-term debt	$	102		$	—		$	—		$	—		$	102
Accounts payable	24			46.2			12.1			—			82.3
Accrued expenses	145.2			71.2			50.1			—			266.5
Deferred revenue	108.5			7.9			30.7			—			147.1
Deferred income tax liability	—			—			—			—			—
Intercompany payables	2,628.50			—			51.5			(2,680.0		)	—
Total current liabilities	3,008.20			125.3			144.4			(2,680.0		)	597.9
Long-term debt, net of current portion	4,168.50			—			—			—			4,168.50
Deferred income tax liabilities	82.6			1,320.10			8.1			—			1,410.80
Deferred service obligations – long-term	8.1			4			9.7			—			21.8
Long-term intercompany payables	144			—			—			(144.0		)	—
Other long-term liabilities	113.7			32.8			35.2			—			181.7
Total stockholders’ equity	2,031.30			8,467.00			431.5			(8,898.5		)	2,031.30
Total liabilities and stockholders’ equity	$	9,556.40		$	9,949.20		$	628.9		$	(11,722.5	)	$	8,412.00
SUPPLEMENTAL CONDENSED CONSOLIDATING BALANCE SHEET
September 28, 2013
	Parent/			Guarantor			Non-Guarantor			Eliminations			Consolidated
	Issuer			Subsidiaries			Subsidiaries
ASSETS
Current assets:
Cash and cash equivalents	$	321.6		$	387.4		$	113.5		$	—		$	822.5
Restricted cash	—			—			6.9			—			6.9
Accounts receivable, net	126.1			174.4			108.8			—			409.3
Inventories	81.9			146.7			60.8			—			289.4
Deferred income tax assets	—			19			0.5			(19.5		)	—
Prepaid income taxes	47.1			2.3			—			(4.7		)	44.7
Prepaid expenses and other current assets	16.3			21.1			11			—			48.4
Intercompany receivables	—			2,442.60			31.9			(2,474.5		)	—
Other current assets – assets held-for-sale	—			—			3			—			3
Total current assets	593			3,193.50			336.4			(2,498.7		)	1,624.20
Property, plant and equipment, net	29.3			356.7			105.5			—			491.5
Intangible assets, net	19.9			3,785.00			101.8			—			3,906.70
Goodwill	283			2,390.90			140.6			—			2,814.50
Other assets	103.6			58.4			1.9			—			163.9
Investments in subsidiaries	8,667.60			129			2.3			(8,798.9		)	—
Total assets	$	9,696.40		$	9,913.50		$	688.5		$	(11,297.6	)	$	9,000.80
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current portion of long-term debt	$	563.8		$	—		$	—		$	—		$	563.8
Accounts payable	27.9			42.6			10			—			80.5
Accrued expenses	153			79.6			44.4			(5.0		)	272
Deferred revenue	93.3			8			31			—			132.3
Deferred income tax liabilities	59.3			—			—			(19.5		)	39.8
Intercompany payables	2,418.10			—			64.4			(2,482.5		)	—
Total current liabilities	3,315.40			130.2			149.8			(2,507.0		)	1,088.40
Long-term debt, net of current portion	4,242.10			—			—			—			4,242.10
Deferred income tax liabilities	89.1			1,435.50			10.7			—			1,535.30
Deferred service obligations – long-term	11.3			3.5			12.9			(2.2		)	25.5
Other long-term liabilities	97			37.6			33.4			—			168
Total stockholders’ equity	1,941.50			8,306.70			481.7			(8,788.4		)	1,941.50
Total liabilities and stockholders’ equity	$	9,696.40		$	9,913.50		$	688.5		$	(11,297.6	)	$	9,000.80
CONSOLIDATING STATEMENT OF CASH FLOWS
For the Nine Months Ended June 28, 2014
	Parent/			Guarantor			Non-Guarantor			Eliminations			Consolidated
	Issuer			Subsidiaries			Subsidiaries
OPERATING ACTIVITIES
Net cash provided by (used in) operating activities	$	412.6		$	(81.1	)	$	45.2		$	—		$	376.7
INVESTING ACTIVITIES
Proceeds from sale of business, net	—			—			2.4			—			2.4
Purchase of property and equipment	(9.4		)	(15.3		)	(6.2		)	—			(30.9		)
Increase in equipment under customer usage agreements	(0.5		)	(15.8		)	(10.6		)	—			(26.9		)
Net sales of insurance contracts	13.8			—			—			—			13.8
Purchases of mutual funds	(29.7		)	—			—			—			(29.7		)
Sales of mutual funds	22.4			—			—			—			22.4
(Increase) decrease in other assets	(1.0		)	(3.0		)	1			—			(3.0		)
Net cash used in investing activities	(4.4		)	(34.1		)	(13.4		)	—			(51.9		)
FINANCING ACTIVITIES
Repayment of long-term debt	(578.8		)	—			—			—			(578.8		)
Payment of debt issuance costs	(2.4		)	—			—			—			(2.4		)
Payment of deferred acquisition consideration	(5.0		)	—			—			—			(5.0		)
Net proceeds from issuance of common stock pursuant to employee stock plans	75.8			—			—			—			75.8
Excess tax benefit related to equity awards	5.2			—			—			—			5.2
Payment of minimum tax withholdings on net share settlement of equity awards	(9.2		)	—			—			—			(9.2		)
Net cash used in financing activities	(514.4		)	—			—			—			(514.4		)
Effect of exchange rate changes on cash and cash equivalents	—			0.4			(0.8		)	—			(0.4		)
Net (decrease) increase in cash and cash equivalents	(106.2		)	(114.8		)	31			—			(190.0		)
Cash and cash equivalents, beginning of period	321.6			387.4			113.5			—			822.5
Cash and cash equivalents, end of period	$	215.4		$	272.6		$	144.5		$	—		$	632.5
CONSOLIDATING STATEMENT OF CASH FLOWS
For the Nine Months Ended June 29, 2013
	Parent/			Guarantor			Non-Guarantor			Eliminations			Consolidated
	Issuer			Subsidiaries			Subsidiaries
OPERATING ACTIVITIES
Net cash provided by operating activities	$	218.4		$	146.4		$	51		$	—		$	415.8
INVESTING ACTIVITIES
Acquisition of a business	(6.1		)	—			(0.2		)	—			(6.3		)
Payment of additional acquisition consideration	(16.8		)	—			—			—			(16.8		)
Proceeds from sale of business, net of cash transferred	—			84.8			1.5			—			86.3
Purchase of property and equipment	(13.1		)	(19.7		)	(8.3		)	—			(41.1		)
Increase in equipment under customer usage agreements	(0.5		)	(18.8		)	(12.6		)	—			(31.9		)
Purchase of insurance contracts	(4.0		)	—			—			—			(4.0		)
Proceeds from sale of intellectual property	—			60			—			—			60
Purchase of cost-method investments	(3.4		)	(0.2		)	—			—			(3.6		)
Sale of cost-method investments	2.1			—			—			—			2.1
Increase in other assets	(2.1		)	(2.1		)	(0.4		)	—			(4.6		)
Net cash provided by (used in) investing activities	(43.9		)	104			(20.0		)	—			40.1
FINANCING ACTIVITIES
Repayment of long-term debt	(48.8		)	—			—			—			(48.8		)
Payment of debt issuance cost	(7.0		)	—			—			—			(7.0		)
Payment of contingent consideration	(42.4		)	—			—			—			(42.4		)
Payment of deferred acquisition consideration	(1.7		)	—			—			—			(1.7		)
Net proceeds from issuance of common stock pursuant to employee stock plans	51.2			—			—			—			51.2
Excess tax benefit related to equity awards	5.4			—			—			—			5.4
Payment of minimum tax withholdings on net share settlements of equity awards	(12.0		)	—			—			—			(12.0		)
Intercompany dividend	175			(175.0		)	—			—			—
Net cash used in financing activities	(55.3		)	—			—			—			(55.3		)
Effect of exchange rate changes on cash and cash equivalents	—			(3.0		)	0.4			—			(2.6		)
Net increase in cash and cash equivalents	119.2			247.4			31.4			—			398
Cash and cash equivalents, beginning of period	210			269.4			81			—			560.4
Cash and cash equivalents, end of period	$	329.2		$	516.8		$	112.4		$	—		$	958.4

New_Accounting_Pronouncements_

New Accounting Pronouncements (Policies)	9 Months Ended
	Jun. 28, 2014
Accounting Changes and Error Corrections [Abstract]	'
New Accounting Pronouncements	'
	New Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 660), which provides guidance for revenue recognition. This ASU is applicable to any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 will supersede the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled to receive in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under current US GAAP. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation.  ASU 2014-09 is effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2016, which is fiscal 2018 for the Company. The Company is currently evaluating the impact of the adoption of ASU 2014-09 on its consolidated financial position and results of operations.
	In April 2014, the FASB issued ASU 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, which amends the guidance for reporting discontinued operations and disposals of components of an entity. The amended guidance requires that a disposal representing a strategic shift in operations, such as a disposal of a major line of business or geographic area, that has (or will have) a major effect on an entity’s financial results should be reported as discontinued operations. ASU 2014-08 also expands the disclosure requirements for discontinued operations and adds new disclosures for individually significant dispositions that do not qualify as discontinued operations. ASU 2014-08 is effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2014 (early adoption is permitted only for disposals that have not been previously reported). The implementation of ASU 2014-08 is not expected to have a material impact on the Company’s consolidated financial position or results of operations.
	In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exist. ASU 2013-11 amends the presentation requirements of ASC 740 and requires an unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, similar tax loss, or a tax credit carryforward. To the extent the tax benefit is not available at the reporting date under the governing tax law or if the entity does not intend to use the deferred tax asset for such purpose, the unrecognized tax benefit should be presented as a liability and not combined with deferred tax assets. The ASU is effective for annual periods, and interim periods within those years, beginning after December 15, 2013, which is fiscal 2015 for the Company. The amendments are to be applied to all unrecognized tax benefits that exist as of the effective date and may be applied retrospectively to each prior reporting period presented. The Company is currently evaluating the impact of the adoption of ASU 2013-11 on its consolidated financial position or results of operations.

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Jun. 28, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Assets and Liabilities Measured on Recurring Basis	'
	Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following at June 28, 2014:
					Fair Value at Reporting Date Using
		Balance as of June 28, 2014			Quoted Prices in				Significant				Significant
					Active Market for				Other				Unobservable
					Identical Assets				Observable				Inputs (Level 3)
					(Level 1)				Inputs (Level 2)
	Assets:
	Marketable securities:
	Equity security	$	20		$	20			$	—			$	—
	Mutual funds	18.3			18.3				—				—
	Total	$	38.3		$	38.3			$	—			$	—
	Liabilities:
	Deferred compensation liabilities	$	36		$	36			$	—			$	—
	Contingent consideration	3.1			—				—				3.1
	Total	$	39.1		$	36			$	—			$	3.1
Changes in Fair Value of Recurring Fair Value Measurements Using Significant Unobservable Inputs (Level 3), Consisting of Contingent Consideration Liabilities	'
	Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of contingent consideration liabilities, were as follows:
		Three Months Ended							Nine Months Ended
		June 28,			June 29,				June 28,				June 29,
		2014			2013				2014				2013
	Balance at beginning of period	$	3.4		$	3.6			$	3.8			$	86.4
	Contingent consideration recorded at acquisition	—			0.5				—				0.5
	Fair value adjustments	—			0.5				—				11.3
	Payments	(0.3		)	(0.1		)		(0.7		)		(93.7		)
	Balance at end of period	$	3.1		$	4.5			$	3.1			$	4.5
Schedule of Estimated Fair Value of Assets Measured on a Nonrecurring Basis	'
	The following chart depicts the level of inputs within the fair value hierarchy used to estimate the fair value of assets measured on a nonrecurring basis for which the Company has recorded impairment charges to date in fiscal 2014:
					Fair Value Measurements Using
		Fair Value			Quoted Prices in			Significant			Significant				Total
					Active Market for			Other			Unobservable				Losses
					Identical Assets			Observable			Inputs (Level 3)
					(Level 1)			Inputs (Level 2)
	Fiscal 2014:
	Intangible assets	$	18.3		—			—			$	18.3			$	(27.1	)
	Property and equipment	1			—			—			1				(1.5		)
	Buildings	1.4			—			—			1.4				(3.1		)
	Cost-method equity investments	0.8			—			—			0.8				(6.9		)
															$	(38.6	)
Estimated Fair Values of Convertible Notes	'
	The estimated fair values of the Company’s Convertible Notes at June 28, 2014 were as follows:
	2010 Notes	$	566.4
	2012 Notes	548.6
	2013 Notes	408.9
		$	1,523.90

Restructuring_and_Divestiture_1

Restructuring and Divestiture Charges (Tables)	9 Months Ended
	Jun. 28, 2014
Restructuring and Related Activities [Abstract]	'
Charges Taken Related to Restructuring Actions	'
	The following table displays charges taken related to restructuring actions in fiscal 2014, 2013 and 2012 and a rollforward of the charges to the accrued balances as of June 28, 2014:
		Consolidation of Diagnostics Operations			Closure of Indianapolis Facility			Fiscal 2014 Actions			Fiscal 2013 Actions			Other Operating Cost Reductions			Total
	Restructuring and Divestiture Charges
	Fiscal 2012 charges:
	Non-cash impairment charge	$	0.6		$	—		$	—		$	—		$	—		$	0.6
	Purchase orders and other contractual obligations	—			—			—			—			0.3			0.3
	Workforce reductions	14.2			0.9			—			—			0.2			15.3
	Facility closure costs	—			—			—			—			0.4			0.4
	Other	—			0.9			—			—			—			0.9
	Fiscal 2012 restructuring and divestiture charges	$	14.8		$	1.8		$	—		$	—		$	0.9		$	17.5
	Fiscal 2013 charges:
	Workforce reductions	$	14		$	4.8		$	—		$	11.3		$	1.1		$	31.2
	Facility closure costs	—			0.2			—			—			0.4			0.6
	Other	—			0.7			—			—			0.2			0.9
	Fiscal 2013 restructuring charges	$	14		$	5.7		$	—		$	11.3		$	1.7		$	32.7
	Divestiture net charges																0.1
	Fiscal 2013 restructuring and divestiture charges																$	32.8
	Fiscal 2014 charges:
	Workforce reductions	$	2.3		$	0.2		$	21		$	0.9		$	8.3		$	32.7
	Property impairment	—			—			—			—			3.1			3.1
	Facility closure costs	—			0.5			—			—			—			0.5
	Other	—			—			—			—			0.1			0.1
	Fiscal 2014 restructuring charges	$	2.3		$	0.7		$	21		$	0.9		$	11.5		$	36.4
	Divestiture net charges																0.2
	Fiscal 2014 restructuring and divestiture charges																$	36.6
Charges Taken Related to Accrued Restructuring Actions	'
		Consolidation of Diagnostics Operations			Closure of Indianapolis Facility			Fiscal 2014 Actions			Fiscal 2013 Actions			Other Operating Cost Reductions			Total
	Rollforward of Accrued Restructuring
	Fiscal 2012 charges	$	14.8		$	1.8		$	—		$	—		$	0.9		$	17.5
	Non-cash impairment charges	(0.6		)	—			—			—			—			(0.6		)
	Stock-based compensation	(3.5		)	—			—			—			—			(3.5		)
	Severance payments	(2.4		)	—			—			—			(0.2		)	(2.6		)
	Other payments	—			—			—			—			(0.8		)	(0.8		)
	Acquired and other	0.1			—			—			—			0.1			0.2
	Balance as of September 29, 2012	$	8.4		$	1.8		$	—		$	—		$	0		$	10.2
	Fiscal 2013 restructuring charges	$	14		$	5.7		$	—		$	11.3		$	1.7		$	32.7
	Stock-based compensation	(6.3		)	—			—			(1.6		)	—			(7.9		)
	Severance payments	(13.1		)	(3.1		)	—			(4.4		)	(0.9		)	(21.5		)
	Other payments	—			(0.6		)	—			—			(0.6		)	(1.2		)
	Balance as of September 28, 2013	$	3		$	3.8		$	—		$	5.3		$	0.2		$	12.3
	Fiscal 2014 restructuring charges	$	2.3		$	0.7		$	21		$	0.9		$	11.5		$	36.4
	Stock-based compensation	—			—			(6.5		)	—			—			(6.5		)
	Non-cash impairment charges	—			—			—			—			(3.1		)	(3.1		)
	Severance payments	(0.9		)	(4.0		)	(7.7		)	(5.9		)	(5.9		)	(24.4		)
	Other payments	—			(0.4		)	—			—			(0.1		)	(0.5		)
	Balance as of June 28, 2014	$	4.4		$	0.1		$	6.8		$	0.3		$	2.6		$	14.2

Borrowings_and_Credit_Arrangem1

Borrowings and Credit Arrangements (Tables)	9 Months Ended
	Jun. 28, 2014
Debt Disclosure [Abstract]	'
Company's Borrowings	'
	The Company’s borrowings consisted of the following:
		June 28,		September 28,
		2014		2013
	Current debt obligations, net of debt discount:
	Term Loan A	$	87.1	$	49.7
	Term Loan B	14.9		114
	Convertible Notes	—		400.1
	Total current debt obligations	102		563.8
	Long-term debt obligations, net of debt discount:
	Term Loan A	821.2		894.8
	Term Loan B	1,124.30		1,159.30
	Senior Notes	1,000.00		1,000.00
	Convertible Notes	1,223.00		1,188.00
	Total long-term debt obligations	4,168.50		4,242.10
	Total debt obligations	$	4,270.50	$	4,805.90
Interest Expense under Convertible Notes	'
	Interest expense under the Convertible Notes is as follows:
		Three Months Ended				Nine Months Ended
		June 28,		June 29,		June 28,		June 29,
		2014		2013		2014		2013
	Amortization of debt discount	$	8.5	$	11.6	$	28.4	$	40.9
	Amortization of deferred financing costs	0.4		0.7		1.5		2.4
	Principal accretion	3.9		3.7		11.4		5.5
	Non-cash interest expense	12.8		16		41.3		48.8
	2.00% accrued interest	4.7		8.6		17.6		25.8
		$	17.5	$	24.6	$	58.9	$	74.6

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	9 Months Ended
	Jun. 28, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Summary of Contingent Consideration Charges Recorded to the Consolidated Statements of Operations	'
	A summary of amounts recorded to the Consolidated Statements of Operations is as follows:
	Statement of Operations Line Item – 3 Months Ended June 29, 2013	Interlace		TCT		Total
	Contingent consideration – compensation expense	$	—	$	21.6	$	21.6
	Contingent consideration – fair value adjustments	0.5		—		0.5
		$	0.5	$	21.6	$	22.1
	Statement of Operations Line Item – 9 Months Ended June 29, 2013	Interlace		TCT		Total
	Contingent consideration – compensation expense	$	—	$	80.5	$	80.5
	Contingent consideration – fair value adjustments	11.3		—		11.3
		$	11.3	$	80.5	$	91.8

Marketable_Securities_Tables

Marketable Securities (Tables)	9 Months Ended
	Jun. 28, 2014
Investments, Debt and Equity Securities [Abstract]	'
Reconciles Cost Basis to Fair Market Value of Company's Equity Security	'
	The following reconciles the cost basis to the fair market value of the Company’s equity security that is classified as available-for-sale:
	Period Ended:	Cost		Gross Unrealized		Gross Unrealized		Fair Value
				Gains		Losses
	28-Jun-14	$	5.9	$	14.1	$	—	$	20
	28-Sep-13	$	5.9	$	12.2	$	—	$	18.1

Net_Income_Loss_Per_Share_Tabl

Net Income (Loss) Per Share (Tables)	9 Months Ended
	Jun. 28, 2014
Earnings Per Share [Abstract]	'
Reconciliation of Basic and Diluted Share Amounts	'
	A reconciliation of basic and diluted share amounts is as follows:
		Three Months Ended		Nine Months Ended
		June 28,	June 29,	June 28,	June 29,
		2014	2013	2014	2013
	Basic weighted average common shares outstanding	276,843	269,430	274,713	267,983
	Weighted average common stock equivalents from assumed exercise of stock options and restricted stock units	2,130	—	—	—
	Incremental shares from assumed conversion of the Convertible Notes premium	232	—	—	—
	Diluted weighted average common shares outstanding	279,205	269,430	274,713	267,983
	Weighted-average anti-dilutive shares related to:
	Outstanding stock options	4,727	7,964	7,007	8,724
	Restricted stock units	21	1,147	811	1,089

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Jun. 28, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation Expense in Consolidated Statements of Operations	'
	The following presents stock-based compensation expense in the Company’s Consolidated Statements of Operations:
		Three Months Ended						Nine Months Ended
		June 28,			June 29,			June 28,			June 29,
		2014			2013			2014			2013
	Cost of revenues	$	1.9		$	1.7		$	5.5		$	5.2
	Research and development	2.2			1.7			6.3			5.6
	Selling and marketing	2			2.2			6.1			7
	General and administrative	5.2			4.7			14.7			16.4
	Restructuring and divestiture	1.7			0.5			6.5			7.7
		$	13		$	10.8		$	39.1		$	41.9
Weighted-Average Assumptions Utilized to Value Stock Options	'
	The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table:
		Three Months Ended						Nine Months Ended
		June 28,			June 29,			June 28,			June 29,
		2014			2013			2014			2013
	Risk-free interest rate	1.3		%	0.5		%	1.2		%	0.5		%
	Expected volatility	41.4		%	43.7		%	41.4		%	43.7		%
	Expected life (in years)	4.5			4.4			4.4			4.4
	Dividend yield	—			—			—			—
	Weighted average fair value of options granted	$	7.97		$	7.47		$	7.64		$	7.09

Other_Balance_Sheet_Informatio1

Other Balance Sheet Information (Tables)	9 Months Ended
	Jun. 28, 2014
Other Balance Sheet Information [Abstract]	'
Other Balance Sheet Information of Inventories	'
		June 28,			September 28,
		2014			2013
	Inventories
	Raw materials	$	121		$	115.6
	Work-in-process	59			51.2
	Finished goods	149.8			122.6
		$	329.8		$	289.4
Other Balance Sheet Information of Property, Plant and Equipment	'
	Property, plant and equipment
	Equipment and software	$	341.6		$	318.5
	Equipment under customer usage agreements	285.3			275.7
	Building and improvements	175.6			171.5
	Leasehold improvements	64.1			68.2
	Land	51.7			51.6
	Furniture and fixtures	16.3			22.5
		934.6			908
	Less – accumulated depreciation and amortization	(467.2		)	(416.5		)
		$	467.4		$	491.5

Business_Segments_and_Geograph1

Business Segments and Geographic Information (Tables)	9 Months Ended
	Jun. 28, 2014
Segment Reporting [Abstract]	'
Segment Information	'
	Segment information is as follows:
		Three Months Ended							Nine Months Ended
		June 28,			June 29,				June 28,			June 29,
		2014			2013				2014			2013
	Total revenues:
	Diagnostics	$	293.1		$	297.4			$	869.7		$	899.8
	Breast Health	238			230				703.2			671
	GYN Surgical	78.5			75.8				229.4			230.4
	Skeletal Health	23			22.9				67.8			69
		$	632.6		$	626.1			$	1,870.10		$	1,870.20
	Operating income (loss):
	Diagnostics	$	4.8		$	(1.2	)		$	24.8		$	(33.7	)
	Breast Health	58.4			53.2				128			146
	GYN Surgical	9.1			6.3				26.8			9.1
	Skeletal Health	3.9			2.8				8.1			8.5
		$	76.2		$	61.1			$	187.7		$	129.9
	Depreciation and amortization:
	Diagnostics	$	95.8		$	92.2			$	282.6		$	273.2
	Breast Health	11.7			10				30.2			30.1
	GYN Surgical	26.3			26.5				78.4			79.5
	Skeletal Health	0.2			0.2				0.6			0.6
		$	134		$	128.9			$	391.8		$	383.4
	Capital expenditures:
	Diagnostics	$	12.8		$	13.4			$	37.9		$	40.6
	Breast Health	2.7			4.2				6.8			13.7
	GYN Surgical	2			2.4				5.9			7.4
	Skeletal Health	—			0.2				0.2			0.4
	Corporate	2.5			6				7			10.9
		$	20		$	26.2			$	57.8		$	73
		June 28,			September 28,
		2014			2013
	Identifiable assets:
	Diagnostics	$	4,468.60		$	4,667.90
	Breast Health	882.8			932.2
	GYN Surgical	1,770.90			1,849.50
	Skeletal Health	25.5			33.5
	Corporate	1,264.20			1,517.70
		$	8,412.00		$	9,000.80
Revenues by Geography	'
	Revenues by geography as a percentage of total revenues were as follows:
		Three Months Ended					Nine Months Ended
		June 28,		June 29,			June 28,			June 29,
		2014		2013			2014			2013
	United States	76	%	75	%		75	%		74	%
	Europe	12	%	13	%		14	%		14	%
	Asia-Pacific	8	%	8	%		7	%		8	%
	All others	4	%	4	%		4	%		4	%
		100	%	100	%		100	%		100	%

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Jun. 28, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Rollforward of Goodwill Activity by Reportable Segment	'
	A rollforward of goodwill activity by reportable segment from September 28, 2013 to June 28, 2014 is as follows:
		Diagnostics			Breast Health			GYN Surgical			Skeletal Health		Total
	Balance at September 28, 2013	$	1,153.50		$	636.4		$	1,016.40		$	8.2	$	2,814.50
	Disposition of a portion of a reporting unit	(0.2		)	—			—			—		(0.2		)
	Tax adjustments	(0.6		)	—			—			—		(0.6		)
	Foreign currency and other	(0.6		)	(1.7		)	(0.3		)	—		(2.6		)
	Balance at June 28, 2014	$	1,152.10		$	634.7		$	1,016.10		$	8.2	$	2,811.10
Schedule of Intangible Assets	'
	Intangible assets consisted of the following:
	Description	As of June 28, 2014						As of September 28, 2013
		Gross			Accumulated			Gross			Accumulated
		Carrying			Amortization			Carrying			Amortization
		Value						Value
	Developed technology	$	3,969.90		$	1,317.60		$	4,009.00		$	1,094.50
	In-process research and development	23			—			24			—
	Customer relationships and contracts	1,101.90			362.5			1,101.90			296.5
	Trade names	236.8			98.8			238.1			81.8
	Patents	14.1			8.8			13			8.5
	Business licenses	2.6			1.9			2.6			0.6
		$	5,348.30		$	1,789.60		$	5,388.60		$	1,481.90
Schedule of Estimated Amortization Expense	'
	The estimated remaining amortization expense as of June 28, 2014 for each of the five succeeding fiscal years is as follows:
	Remainder of Fiscal 2014	$	109.5
	Fiscal 2015	$	414.6
	Fiscal 2016	$	374.5
	Fiscal 2017	$	365.4
	Fiscal 2018	$	354.9

Product_Warranties_Tables

Product Warranties (Tables)	9 Months Ended
	Jun. 28, 2014
Guarantees [Abstract]	'
Product Warranty	'
	Product warranty activity was as follows:
		Balance at		Provisions		Settlements/			Balance at
		Beginning of				Adjustments			End of Period
		Period
	Nine Months Ended:
	28-Jun-14	$	9.3	$	5.5	$	(7.5	)	$	7.3
	29-Jun-13	$	6.2	$	8.8	$	(7.2	)	$	7.8

Supplemental_Guarantor_Condens1

Supplemental Guarantor Condensed Consolidating Financials (Tables)	9 Months Ended
	Jun. 28, 2014
Condensed Financial Information of Parent Company Only Disclosure [Abstract]	'
Schedule of Supplemental Condensed Consolidating Statement of Operations	'
	SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS
	For the Three Months Ended June 28, 2014
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
	Revenues:
	Product	$	128.4		$	386.4		$	125.8		$	(111.3	)	$	529.3
	Service and other	88.2			14.4			13.1			(12.4		)	103.3
		216.6			400.8			138.9			(123.7		)	632.6
	Costs of revenues:
	Product	61.5			147.3			89.2			(111.3		)	186.7
	Amortization of intangible assets	1.4			75.3			3.8			—			80.5
	Service and other	46.8			5.9			12.3			(12.4		)	52.6
	Gross Profit	106.9			172.3			33.6			—			312.8
	Operating expenses:
	Research and development	7.7			42.9			1.9			—			52.5
	Selling and marketing	16.8			43.4			22.8			—			83
	General and administrative	15.8			37.8			11.1			—			64.7
	Amortization of intangible assets	0.6			26.8			2.3			—			29.7
	Restructuring and divestiture charges	1			2.9			2.8			—			6.7
		41.9			153.8			40.9			—			236.6
	Income (loss) from operations	65			18.5			(7.3		)	—			76.2
	Interest income	0.1			1.1			0.2			(1.1		)	0.3
	Interest expense	(52.6		)	(0.3		)	(0.6		)	1.1			(52.4		)
	Other (expense) income, net	1.3			(3.0		)	0.2			—			(1.5		)
	Income (loss) before income taxes	13.8			16.3			(7.5		)	—			22.6
	Provision for income taxes	6.8			3.6			0.9			—			11.3
	Equity in earnings (losses) of subsidiaries	4.3			3.3			—			(7.6		)	—
	Net income (loss)	$	11.3		$	16		$	(8.4	)	$	(7.6	)	$	11.3
	SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS
	For the Nine Months Ended June 28, 2014
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
	Revenues:
	Product	$	356.8		$	1,154.00		$	373.7		$	(321.7	)	$	1,562.80
	Service and other	262.7			47.4			37.2			(40.0		)	307.3
		619.5			1,201.40			410.9			(361.7		)	1,870.10
	Costs of revenues:
	Product	172.4			431.7			266.9			(321.7		)	549.3
	Amortization of intangible assets	4.2			224			5.9			—			234.1
	Impairment of intangible assets	—			—			26.6			—			26.6
	Service and other	140.3			27.5			31.8			(40.0		)	159.6
	Gross Profit	302.6			518.2			79.7			—			900.5
	Operating expenses:
	Research and development	23			121.7			6.4			—			151.1
	Selling and marketing	52.6			126.8			65.6			—			245
	General and administrative	45.5			114.9			34.2			—			194.6
	Amortization of intangible assets	2.4			77.9			4.7			—			85
	Impairment of intangible assets	—			—			0.5			—			0.5
	Restructuring and divestiture charges	7.6			15			14			—			36.6
		131.1			456.3			125.4			—			712.8
	Income (loss) from operations	171.5			61.9			(45.7		)	—			187.7
	Interest income	0.3			2.3			0.7			(2.5		)	0.8
	Interest expense	(168.0		)	(0.8		)	(1.8		)	2.5			(168.1		)
	Debt extinguishment loss	(7.4		)	—			—			—			(7.4		)
	Other (expense) income, net	7.9			(12.4		)	1			—			(3.5		)
	Income (loss) before income taxes	4.3			51			(45.8		)	—			9.5
	Provision for income taxes	5			9.9			5.4			—			20.3
	Equity in earnings (losses) of subsidiaries	(10.1		)	14.3			—			(4.2		)	—
	Net (loss) income	$	(10.8	)	$	55.4		$	(51.2	)	$	(4.2	)	$	(10.8	)
	SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS
	For the Three Months Ended June 29, 2013
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
Revenues:
Product	$	106.5		$	399.1		$	114.8		$	(90.5	)	$	529.9
Service and other	81.4			15.9			11.3			(12.4		)	96.2
	187.9			415			126.1			(102.9		)	626.1
Costs of revenues:
Product	57.7			143.8			76.6			(90.5		)	187.6
Amortization of intangible assets	1.3			73.7			1			—			76
Impairment of intangible assets	—			—			1.7			—			1.7
Service and other	39.1			14.8			9.5			(12.4		)	51
Gross profit	89.8			182.7			37.3			—			309.8
Operating expenses:
Research and development	8			37.2			2.6			—			47.8
Selling and marketing	17.9			43.5			21.5			—			82.9
General and administrative	20			31.3			9.2			—			60.5
Amortization of intangible assets	0.8			26.7			1.2			—			28.7
Contingent consideration – compensation expense	21.6			—			—			—			21.6
Contingent consideration – fair value adjustments	0.5			—			—			—			0.5
Restructuring and divestiture charges	0.6			3.7			2.4			—			6.7
	69.4			142.4			36.9			—			248.7
Income from operations	20.4			40.3			0.4			—			61.1
Interest income	0.1			—			0.2			—			0.3
Interest expense	(66.3		)	(0.3		)	(0.6		)	—			(67.2		)
Other (expense) income, net	178.1			(179.2		)	(0.1		)	—			(1.2		)
(Loss) income before income taxes	132.3			(139.2		)	(0.1		)	—			(7.0		)
Provision (benefit) for income taxes	50.9			(49.9		)	3			—			4
Equity in earnings (losses) of subsidiaries	(92.4		)	1.1			—			91.3			—
Net (loss) income	$	(11.0	)	$	(88.2	)	$	(3.1	)	$	91.3		$	(11.0	)
SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS
For the Nine Months Ended June 29, 2013
	Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
				Subsidiaries			Subsidiaries
Revenues:
Product	$	305.2		$	1,177.70		$	365.3		$	(268.9	)	$	1,579.30
Service and other	240.5			56.5			34.6			(40.7		)	290.9
	545.7			1,234.20			399.9			(309.6		)	1,870.20
Costs of revenues:
Product	163.7			478.1			244.3			(268.9		)	617.2
Amortization of intangible assets	4			219.8			3.2			—			227
Impairment of intangible assets	—			—			1.7			—			1.7
Service and other	118.1			46.2			29.9			(40.7		)	153.5
Gross profit	259.9			490.1			120.8			—			870.8
Operating expenses:
Research and development	22.7			118.8			7.4			—			148.9
Selling and marketing	59.1			136.2			70.1			—			265.4
General and administrative	52			101			26.7			—			179.7
Amortization of intangible assets	2.2			80.1			3.6			—			85.9
Contingent consideration – compensation expense	80.5			—			—			—			80.5
Contingent consideration – fair value adjustments	11.3			—			—			—			11.3
Gain on sale of intellectual property	—			(53.9		)	—			—			(53.9		)
Restructuring and divestiture charges	0.9			17.7			4.5			—			23.1
	228.7			399.9			112.3			—			740.9
Income from operations	31.2			90.2			8.5			—			129.9
Interest income	0.4			0.1			0.3			—			0.8
Interest expense	(212.9		)	(0.9		)	(1.5		)	—			(215.3		)
Debt extinguishment loss	(3.2		)	—			—			—			(3.2		)
Other income (expense), net	179.8			(186.3		)	6.3			—			(0.2		)
(Loss) income before income taxes	(4.7		)	(96.9		)	13.6			—			(88.0		)
(Benefit) provision for income taxes	24.3			(61.1		)	7.7			—			(29.1		)
Equity in earnings (losses) of subsidiaries	(29.9		)	14.5			—			15.4			—
Net (loss) income	$	(58.9	)	$	(21.3	)	$	5.9		$	15.4		$	(58.9	)
Schedule of Supplemental Condensed Consolidating Statements of Comprehensive (Loss) Income	'
	SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
	For the Three Months Ended June 28, 2014
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
	Net income (loss)	$	11.3		$	16		$	(8.4	)	$	(7.6	)	$	11.3
	Changes in foreign currency translation adjustment	—			0.3			3			—			3.3
	Changes in unrealized holding gain on available-for-sale securities	—			4.2			—			—			4.2
	Comprehensive income (loss)	$	11.3		$	20.5		$	(5.4	)	$	(7.6	)	$	18.8
	For the Nine Months Ended June 28, 2014
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
	Net (loss) income	$	(10.8	)	$	55.4		$	(51.2	)	$	(4.2	)	$	(10.8	)
	Changes in foreign currency translation adjustment	—			0.4			(4.1		)	—			(3.7		)
	Changes in unrealized holding gain on available-for-sale securities	—			1.9			—			—			1.9
	Changes in pension plans, net of taxes	—			—			(0.6		)	—			(0.6		)
	Comprehensive (loss) income	$	(10.8	)	$	57.7		$	(55.9	)	$	(4.2	)	$	(13.2	)
	For the Three Months Ended June 29, 2013
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
	Net (loss) income	$	(11.0	)	$	(88.2	)	$	(3.1	)	$	91.3		$	(11.0	)
	Changes in foreign currency translation adjustment	—			—			(2.9		)	—			(2.9		)
	Changes in unrealized holding gain on available-for-sale securities	—			0.1			—			—			0.1
	Comprehensive (loss) income	$	(11.0	)	$	(88.1	)	$	(6.0	)	$	91.3		$	(13.8	)
	For the Nine Months Ended June 29, 2013
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
	Net (loss) income	$	(58.9	)	$	(21.3	)	$	5.9		$	15.4		$	(58.9	)
	Changes in foreign currency translation adjustment	—			0.2			(9.5		)	—			(9.3		)
	Changes in unrealized holding gain on available-for-sale securities	—			2.3			—			—			2.3
	Comprehensive (loss) income	$	(58.9	)	$	(18.8	)	$	(3.6	)	$	15.4		$	(65.9	)
Schedule of Supplemental Condensed Consolidating Balance Sheet	'
	SUPPLEMENTAL CONDENSED CONSOLIDATING BALANCE SHEET
	June 28, 2014
		Parent/			Guarantor			Non-Guarantor			Eliminations			Consolidated
		Issuer			Subsidiaries			Subsidiaries
	ASSETS
	Current assets:
	Cash and cash equivalents	$	215.4		$	272.6		$	144.5		$	—		$	632.5
	Restricted cash	—			—			5.9			—			5.9
	Accounts receivable, net	114.3			168.7			98.7			—			381.7
	Inventories	88.8			186.1			54.9			—			329.8
	Deferred income tax assets	14.4			19.2			0.8			—			34.4
	Prepaid income taxes	6			2.9			1.4			—			10.3
	Prepaid expenses and other current assets	18.7			10.1			9			—			37.8
	Intercompany receivables	—			2,663.60			13.4			(2,677.0		)	—
	Total current assets	457.6			3,323.20			328.6			(2,677.0		)	1,432.40
	Property, plant and equipment, net	29.2			338			100.2			—			467.4
	Intangible assets, net	14.1			3,484.20			60.4			—			3,558.70
	Goodwill	282.4			2,391.00			137.7			—			2,811.10
	Other assets	92.1			48.5			1.8			—			142.4
	Long term intercompany receivables	—			144			—			(144.0		)	—
	Investment in subsidiaries	8,681.00			220.3			0.2			(8,901.5		)	—
	Total assets	$	9,556.40		$	9,949.20		$	628.9		$	(11,722.5	)	$	8,412.00
	LIABILITIES AND STOCKHOLDERS’ EQUITY
	Current liabilities:
	Current portion of long-term debt	$	102		$	—		$	—		$	—		$	102
	Accounts payable	24			46.2			12.1			—			82.3
	Accrued expenses	145.2			71.2			50.1			—			266.5
	Deferred revenue	108.5			7.9			30.7			—			147.1
	Deferred income tax liability	—			—			—			—			—
	Intercompany payables	2,628.50			—			51.5			(2,680.0		)	—
	Total current liabilities	3,008.20			125.3			144.4			(2,680.0		)	597.9
	Long-term debt, net of current portion	4,168.50			—			—			—			4,168.50
	Deferred income tax liabilities	82.6			1,320.10			8.1			—			1,410.80
	Deferred service obligations – long-term	8.1			4			9.7			—			21.8
	Long-term intercompany payables	144			—			—			(144.0		)	—
	Other long-term liabilities	113.7			32.8			35.2			—			181.7
	Total stockholders’ equity	2,031.30			8,467.00			431.5			(8,898.5		)	2,031.30
	Total liabilities and stockholders’ equity	$	9,556.40		$	9,949.20		$	628.9		$	(11,722.5	)	$	8,412.00
	SUPPLEMENTAL CONDENSED CONSOLIDATING BALANCE SHEET
	September 28, 2013
		Parent/			Guarantor			Non-Guarantor			Eliminations			Consolidated
		Issuer			Subsidiaries			Subsidiaries
	ASSETS
	Current assets:
	Cash and cash equivalents	$	321.6		$	387.4		$	113.5		$	—		$	822.5
	Restricted cash	—			—			6.9			—			6.9
	Accounts receivable, net	126.1			174.4			108.8			—			409.3
	Inventories	81.9			146.7			60.8			—			289.4
	Deferred income tax assets	—			19			0.5			(19.5		)	—
	Prepaid income taxes	47.1			2.3			—			(4.7		)	44.7
	Prepaid expenses and other current assets	16.3			21.1			11			—			48.4
	Intercompany receivables	—			2,442.60			31.9			(2,474.5		)	—
	Other current assets – assets held-for-sale	—			—			3			—			3
	Total current assets	593			3,193.50			336.4			(2,498.7		)	1,624.20
	Property, plant and equipment, net	29.3			356.7			105.5			—			491.5
	Intangible assets, net	19.9			3,785.00			101.8			—			3,906.70
	Goodwill	283			2,390.90			140.6			—			2,814.50
	Other assets	103.6			58.4			1.9			—			163.9
	Investments in subsidiaries	8,667.60			129			2.3			(8,798.9		)	—
	Total assets	$	9,696.40		$	9,913.50		$	688.5		$	(11,297.6	)	$	9,000.80
	LIABILITIES AND STOCKHOLDERS’ EQUITY
	Current liabilities:
	Current portion of long-term debt	$	563.8		$	—		$	—		$	—		$	563.8
Accounts payable	27.9			42.6			10			—			80.5
Accrued expenses	153			79.6			44.4			(5.0		)	272
Deferred revenue	93.3			8			31			—			132.3
Deferred income tax liabilities	59.3			—			—			(19.5		)	39.8
Intercompany payables	2,418.10			—			64.4			(2,482.5		)	—
Total current liabilities	3,315.40			130.2			149.8			(2,507.0		)	1,088.40
Long-term debt, net of current portion	4,242.10			—			—			—			4,242.10
Deferred income tax liabilities	89.1			1,435.50			10.7			—			1,535.30
Deferred service obligations – long-term	11.3			3.5			12.9			(2.2		)	25.5
Other long-term liabilities	97			37.6			33.4			—			168
Total stockholders’ equity	1,941.50			8,306.70			481.7			(8,788.4		)	1,941.50
Total liabilities and stockholders’ equity	$	9,696.40		$	9,913.50		$	688.5		$	(11,297.6	)	$	9,000.80
Schedule of Consolidating Statement of Cash Flows	'
	CONSOLIDATING STATEMENT OF CASH FLOWS
	For the Nine Months Ended June 28, 2014
		Parent/			Guarantor			Non-Guarantor			Eliminations			Consolidated
		Issuer			Subsidiaries			Subsidiaries
	OPERATING ACTIVITIES
	Net cash provided by (used in) operating activities	$	412.6		$	(81.1	)	$	45.2		$	—		$	376.7
	INVESTING ACTIVITIES
	Proceeds from sale of business, net	—			—			2.4			—			2.4
	Purchase of property and equipment	(9.4		)	(15.3		)	(6.2		)	—			(30.9		)
	Increase in equipment under customer usage agreements	(0.5		)	(15.8		)	(10.6		)	—			(26.9		)
	Net sales of insurance contracts	13.8			—			—			—			13.8
	Purchases of mutual funds	(29.7		)	—			—			—			(29.7		)
	Sales of mutual funds	22.4			—			—			—			22.4
	(Increase) decrease in other assets	(1.0		)	(3.0		)	1			—			(3.0		)
	Net cash used in investing activities	(4.4		)	(34.1		)	(13.4		)	—			(51.9		)
	FINANCING ACTIVITIES
	Repayment of long-term debt	(578.8		)	—			—			—			(578.8		)
	Payment of debt issuance costs	(2.4		)	—			—			—			(2.4		)
	Payment of deferred acquisition consideration	(5.0		)	—			—			—			(5.0		)
	Net proceeds from issuance of common stock pursuant to employee stock plans	75.8			—			—			—			75.8
	Excess tax benefit related to equity awards	5.2			—			—			—			5.2
	Payment of minimum tax withholdings on net share settlement of equity awards	(9.2		)	—			—			—			(9.2		)
	Net cash used in financing activities	(514.4		)	—			—			—			(514.4		)
	Effect of exchange rate changes on cash and cash equivalents	—			0.4			(0.8		)	—			(0.4		)
	Net (decrease) increase in cash and cash equivalents	(106.2		)	(114.8		)	31			—			(190.0		)
	Cash and cash equivalents, beginning of period	321.6			387.4			113.5			—			822.5
	Cash and cash equivalents, end of period	$	215.4		$	272.6		$	144.5		$	—		$	632.5
	CONSOLIDATING STATEMENT OF CASH FLOWS
	For the Nine Months Ended June 29, 2013
		Parent/			Guarantor			Non-Guarantor			Eliminations			Consolidated
		Issuer			Subsidiaries			Subsidiaries
	OPERATING ACTIVITIES
	Net cash provided by operating activities	$	218.4		$	146.4		$	51		$	—		$	415.8
	INVESTING ACTIVITIES
	Acquisition of a business	(6.1		)	—			(0.2		)	—			(6.3		)
	Payment of additional acquisition consideration	(16.8		)	—			—			—			(16.8		)
	Proceeds from sale of business, net of cash transferred	—			84.8			1.5			—			86.3
	Purchase of property and equipment	(13.1		)	(19.7		)	(8.3		)	—			(41.1		)
	Increase in equipment under customer usage agreements	(0.5		)	(18.8		)	(12.6		)	—			(31.9		)
	Purchase of insurance contracts	(4.0		)	—			—			—			(4.0		)
	Proceeds from sale of intellectual property	—			60			—			—			60
	Purchase of cost-method investments	(3.4		)	(0.2		)	—			—			(3.6		)
	Sale of cost-method investments	2.1			—			—			—			2.1
	Increase in other assets	(2.1		)	(2.1		)	(0.4		)	—			(4.6		)
	Net cash provided by (used in) investing activities	(43.9		)	104			(20.0		)	—			40.1
	FINANCING ACTIVITIES
	Repayment of long-term debt	(48.8		)	—			—			—			(48.8		)
	Payment of debt issuance cost	(7.0		)	—			—			—			(7.0		)
	Payment of contingent consideration	(42.4		)	—			—			—			(42.4		)
	Payment of deferred acquisition consideration	(1.7		)	—			—			—			(1.7		)
	Net proceeds from issuance of common stock pursuant to employee stock plans	51.2			—			—			—			51.2
	Excess tax benefit related to equity awards	5.4			—			—			—			5.4
	Payment of minimum tax withholdings on net share settlements of equity awards	(12.0		)	—			—			—			(12.0		)
	Intercompany dividend	175			(175.0		)	—			—			—
	Net cash used in financing activities	(55.3		)	—			—			—			(55.3		)
	Effect of exchange rate changes on cash and cash equivalents	—			(3.0		)	0.4			—			(2.6		)
	Net increase in cash and cash equivalents	119.2			247.4			31.4			—			398
	Cash and cash equivalents, beginning of period	210			269.4			81			—			560.4
	Cash and cash equivalents, end of period	$	329.2		$	516.8		$	112.4		$	—		$	958.4

Fair_Value_Measurements_Fair_V

Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) (USD $)	Jun. 28, 2014
In Millions, unless otherwise specified
Assets:	'
Assets measured at fair value on a recurring basis	$38.30
Liabilities:	'
Liabilities measured at fair value on a recurring basis	39.1
Equity Security [Member]	'
Assets:	'
Assets measured at fair value on a recurring basis	20
Mutual Funds [Member]	'
Assets:	'
Assets measured at fair value on a recurring basis	18.3
Deferred Compensation Liabilities [Member]	'
Liabilities:	'
Liabilities measured at fair value on a recurring basis	36
Contingent Consideration [Member]	'
Liabilities:	'
Liabilities measured at fair value on a recurring basis	3.1
Quoted Prices in Active Market for Identical Assets (Level 1) [Member]	'
Assets:	'
Assets measured at fair value on a recurring basis	38.3
Liabilities:	'
Liabilities measured at fair value on a recurring basis	36
Quoted Prices in Active Market for Identical Assets (Level 1) [Member] | Equity Security [Member]	'
Assets:	'
Assets measured at fair value on a recurring basis	20
Quoted Prices in Active Market for Identical Assets (Level 1) [Member] | Mutual Funds [Member]	'
Assets:	'
Assets measured at fair value on a recurring basis	18.3
Quoted Prices in Active Market for Identical Assets (Level 1) [Member] | Deferred Compensation Liabilities [Member]	'
Liabilities:	'
Liabilities measured at fair value on a recurring basis	36
Quoted Prices in Active Market for Identical Assets (Level 1) [Member] | Contingent Consideration [Member]	'
Liabilities:	'
Liabilities measured at fair value on a recurring basis	0
Significant Other Observable Inputs (Level 2) [Member]	'
Assets:	'
Assets measured at fair value on a recurring basis	0
Liabilities:	'
Liabilities measured at fair value on a recurring basis	0
Significant Other Observable Inputs (Level 2) [Member] | Equity Security [Member]	'
Assets:	'
Assets measured at fair value on a recurring basis	0
Significant Other Observable Inputs (Level 2) [Member] | Mutual Funds [Member]	'
Assets:	'
Assets measured at fair value on a recurring basis	0
Significant Other Observable Inputs (Level 2) [Member] | Deferred Compensation Liabilities [Member]	'
Liabilities:	'
Liabilities measured at fair value on a recurring basis	0
Significant Other Observable Inputs (Level 2) [Member] | Contingent Consideration [Member]	'
Liabilities:	'
Liabilities measured at fair value on a recurring basis	0
Significant Unobservable Inputs (Level 3) [Member]	'
Assets:	'
Assets measured at fair value on a recurring basis	0
Liabilities:	'
Liabilities measured at fair value on a recurring basis	3.1
Significant Unobservable Inputs (Level 3) [Member] | Equity Security [Member]	'
Assets:	'
Assets measured at fair value on a recurring basis	0
Significant Unobservable Inputs (Level 3) [Member] | Mutual Funds [Member]	'
Assets:	'
Assets measured at fair value on a recurring basis	0
Significant Unobservable Inputs (Level 3) [Member] | Deferred Compensation Liabilities [Member]	'
Liabilities:	'
Liabilities measured at fair value on a recurring basis	0
Significant Unobservable Inputs (Level 3) [Member] | Contingent Consideration [Member]	'
Liabilities:	'
Liabilities measured at fair value on a recurring basis	$3.10

Fair_Value_Measurements_Change

Fair Value Measurements - Changes in Fair Value of Recurring Fair Value Measurements Using Significant Unobservable Inputs (Level 3), Consisting of Contingent Consideration Liabilities (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'	'	'	'
Balance at beginning of period	$3.40	$3.60	$3.80	$86.40
Contingent consideration recorded at acquisition	0	0.5	0	0.5
Fair value adjustments	0	0.5	0	11.3
Payments	-0.3	-0.1	-0.7	-93.7
Balance at end of period	$3.10	$4.50	$3.10	$4.50

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	3 Months Ended					9 Months Ended
	Jun. 28, 2014	Mar. 29, 2014	Dec. 28, 2013	Sep. 28, 2013	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]	'	'	'	'	'	'	'
Impairment charge	'	$28,600,000	'	$700,000	'	'	'
Impairment charge allocated to intangible assets	'	27,100,000	'	'	'	'	'
Impairment charge allocated to property and equipment	'	'	'	'	'	33,300,000	1,800,000
Asset impairment charge	'	'	3,100,000	'	'	'	'
Cost-method equity investments in non-publicly traded securities	5,200,000	'	'	12,600,000	'	5,200,000	'
Other-than-temporary impairment charges	3,200,000	'	'	'	4,700,000	6,900,000	6,400,000
Property and equipment [Member]	'	'	'	'	'	'	'
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]	'	'	'	'	'	'	'
Impairment charge allocated to property and equipment	'	1,500,000	'	'	'	'	'
Cost of product revenues [Member]	'	'	'	'	'	'	'
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]	'	'	'	'	'	'	'
Impairment charge allocated to property and equipment	'	300,000	'	'	'	'	'
General and Administrative Expenses [Member]	'	'	'	'	'	'	'
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]	'	'	'	'	'	'	'
Impairment charge allocated to property and equipment	'	1,200,000	'	'	'	'	'
Credit Agreement [Member]	'	'	'	'	'	'	'
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]	'	'	'	'	'	'	'
Borrowed principal under credit agreement	2,060,000,000	'	'	'	'	2,060,000,000	'
Senior Notes [Member]	'	'	'	'	'	'	'
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]	'	'	'	'	'	'	'
Fair value of debt instrument	$1,060,000,000	'	'	'	'	$1,060,000,000	'

Fair_Value_Measurements_Schedu

Fair Value Measurements - Schedule of Estimated Fair Value of Assets Measured on a Nonrecurring Basis (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Mar. 29, 2014	Dec. 28, 2013	Jun. 28, 2014	Jun. 29, 2013
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Intangible asset, Total Losses	($27.10)	'	'	'
Total Losses	'	-3.1	'	'
Cost-method equity investments, Total Losses	'	'	-6.9	-6.4
Fair Value, Measurements, Nonrecurring [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Intangible assets	'	'	18.3	'
Cost-method equity investments	'	'	0.8	'
Intangible asset, Total Losses	'	'	-27.1	'
Cost-method equity investments, Total Losses	'	'	-6.9	'
Total Losses	'	'	-38.6	'
Fair Value, Measurements, Nonrecurring [Member] | Quoted Prices in Active Market for Identical Assets (Level 1) [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Intangible assets	'	'	0	'
Cost-method equity investments	'	'	0	'
Fair Value, Measurements, Nonrecurring [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Intangible assets	'	'	0	'
Cost-method equity investments	'	'	0	'
Fair Value, Measurements, Nonrecurring [Member] | Significant Unobservable Inputs (Level 3) [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Intangible assets	'	'	18.3	'
Cost-method equity investments	'	'	0.8	'
Fair Value, Measurements, Nonrecurring [Member] | Property and equipment [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Fair value	'	'	1	'
Total Losses	'	'	-1.5	'
Fair Value, Measurements, Nonrecurring [Member] | Property and equipment [Member] | Quoted Prices in Active Market for Identical Assets (Level 1) [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Fair value	'	'	0	'
Fair Value, Measurements, Nonrecurring [Member] | Property and equipment [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Fair value	'	'	0	'
Fair Value, Measurements, Nonrecurring [Member] | Property and equipment [Member] | Significant Unobservable Inputs (Level 3) [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Fair value	'	'	1	'
Fair Value, Measurements, Nonrecurring [Member] | Buildings [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Fair value	'	'	1.4	'
Total Losses	'	'	-3.1	'
Fair Value, Measurements, Nonrecurring [Member] | Buildings [Member] | Quoted Prices in Active Market for Identical Assets (Level 1) [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Fair value	'	'	0	'
Fair Value, Measurements, Nonrecurring [Member] | Buildings [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Fair value	'	'	0	'
Fair Value, Measurements, Nonrecurring [Member] | Buildings [Member] | Significant Unobservable Inputs (Level 3) [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Fair value	'	'	$1.40	'

Fair_Value_Measurements_Estima

Fair Value Measurements - Estimated Fair Values of Convertible Notes (Detail) (USD $)	Jun. 28, 2014
In Millions, unless otherwise specified
Estimated Fair Value Of Financial Instruments [Line Items]	'
Estimated fair values of debt instruments	$1,523.90
2010 Notes [Member]	'
Estimated Fair Value Of Financial Instruments [Line Items]	'
Estimated fair values of debt instruments	566.4
2012 Notes [Member]	'
Estimated Fair Value Of Financial Instruments [Line Items]	'
Estimated fair values of debt instruments	548.6
2013 Notes [Member]	'
Estimated Fair Value Of Financial Instruments [Line Items]	'
Estimated fair values of debt instruments	$408.90

Restructuring_and_Divestiture_2

Restructuring and Divestiture Charges - Charges Taken Related to Restructuring Actions (Detail) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

In Millions, unless otherwise specified

Jun. 28, 2014

Jun. 29, 2013

Jun. 28, 2014

Jun. 29, 2013

Sep. 29, 2012

Sep. 28, 2013

Jun. 28, 2014

Sep. 29, 2012

Sep. 28, 2013

Jun. 28, 2014

Sep. 29, 2012

Sep. 28, 2013

Jun. 28, 2014

Sep. 29, 2012

Sep. 28, 2013

Jun. 28, 2014

Sep. 29, 2012

Sep. 28, 2013

Jun. 28, 2014

Sep. 29, 2012

Sep. 28, 2013

Jun. 28, 2014

Fiscal 2012 Charges [Member]

Fiscal 2013 Charges [Member]

Fiscal 2014 Charges [Member]

Consolidation of Diagnostics Operations [Member]

Consolidation of Diagnostics Operations [Member]

Consolidation of Diagnostics Operations [Member]

Closure of Indianapolis Facility [Member]

Closure of Indianapolis Facility [Member]

Closure of Indianapolis Facility [Member]

Fiscal 2014 Actions [Member]

Fiscal 2014 Actions [Member]

Fiscal 2014 Actions [Member]

Fiscal 2013 Actions [Member]

Fiscal 2013 Actions [Member]

Fiscal 2013 Actions [Member]

Other Operating Cost Reductions [Member]

Other Operating Cost Reductions [Member]

Other Operating Cost Reductions [Member]

Restructuring [Member]

Restructuring [Member]

Restructuring [Member]

Fiscal 2012 Charges [Member]

Fiscal 2013 Charges [Member]

Fiscal 2014 Charges [Member]

Fiscal 2012 Charges [Member]

Fiscal 2013 Charges [Member]

Fiscal 2014 Charges [Member]

Fiscal 2012 Charges [Member]

Fiscal 2013 Charges [Member]

Fiscal 2014 Charges [Member]

Fiscal 2012 Charges [Member]

Fiscal 2013 Charges [Member]

Fiscal 2014 Charges [Member]

Fiscal 2012 Charges [Member]

Fiscal 2013 Charges [Member]

Fiscal 2014 Charges [Member]

Restructuring [Member]

Restructuring [Member]

Restructuring [Member]

Restructuring [Member]

Restructuring [Member]

Restructuring [Member]

Restructuring [Member]

Restructuring [Member]

Restructuring [Member]

Restructuring [Member]

Restructuring [Member]

Restructuring [Member]

Restructuring [Member]

Restructuring [Member]

Restructuring [Member]

Restructuring Cost and Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Asset impairment charges

'

'

$33.30

$1.80

$0.60

'

$3.10

$0.60

'

$0

$0

'

$0

$0

'

$0

$0

'

$0

$0

'

$3.10

Purchase orders and other contractual obligations

'

'

'

'

0.3

'

'

0

'

'

0

'

'

0

'

'

0

'

'

0.3

'

'

Workforce reductions

'

'

'

'

15.3

31.2

32.7

14.2

14

2.3

0.9

4.8

0.2

0

0

21

0

11.3

0.9

0.2

1.1

8.3

Facility closure costs

'

'

'

'

0.4

0.6

0.5

0

0

0

0

0.2

0.5

0

0

0

0

0

0

0.4

0.4

0

Other

'

'

'

'

0.9

0.9

0.1

0

0

0

0.9

0.7

0

0

0

0

0

0

0

0

0.2

0.1

Fiscal restructuring charges

'

'

'

'

17.5

32.7

36.4

14.8

14

2.3

1.8

5.7

0.7

0

0

21

0

11.3

0.9

0.9

1.7

11.5

Divestiture net charges

'

'

'

'

'

0.1

0.2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fiscal restructuring and divestiture charges

$6.70

$6.70

$36.60

$23.10

$17.50

$32.80

$36.60

$14.80

'

'

$1.80

'

'

$0

'

'

$0

'

'

$0.90

'

'

Restructuring_and_Divestiture_3

Restructuring and Divestiture Charges - Charges Taken Related to Accrued Restructuring Actions (Detail) (USD $)	9 Months Ended		12 Months Ended												9 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Sep. 29, 2012	Sep. 29, 2012	Sep. 29, 2012	Sep. 29, 2012	Sep. 29, 2012	Sep. 29, 2012	Sep. 28, 2013	Sep. 28, 2013	Sep. 28, 2013	Sep. 28, 2013	Sep. 28, 2013	Sep. 28, 2013	Jun. 28, 2014	Jun. 28, 2014	Jun. 28, 2014	Jun. 28, 2014	Jun. 28, 2014	Jun. 28, 2014
			Fiscal 2012 Charges [Member]	Fiscal 2012 Charges [Member]	Fiscal 2012 Charges [Member]	Fiscal 2012 Charges [Member]	Fiscal 2012 Charges [Member]	Fiscal 2012 Charges [Member]	Fiscal 2013 Charges [Member]	Fiscal 2013 Charges [Member]	Fiscal 2013 Charges [Member]	Fiscal 2013 Charges [Member]	Fiscal 2013 Charges [Member]	Fiscal 2013 Charges [Member]	Fiscal 2014 Charges [Member]	Fiscal 2014 Charges [Member]	Fiscal 2014 Charges [Member]	Fiscal 2014 Charges [Member]	Fiscal 2014 Charges [Member]	Fiscal 2014 Charges [Member]
			Restructuring [Member]	Consolidation of Diagnostics Operations [Member]	Closure of Indianapolis Facility [Member]	Fiscal 2014 Actions [Member]	Fiscal 2013 Actions [Member]	Other Operating Cost Reductions [Member]	Restructuring [Member]	Consolidation of Diagnostics Operations [Member]	Closure of Indianapolis Facility [Member]	Fiscal 2014 Actions [Member]	Fiscal 2013 Actions [Member]	Other Operating Cost Reductions [Member]	Restructuring [Member]	Consolidation of Diagnostics Operations [Member]	Closure of Indianapolis Facility [Member]	Fiscal 2014 Actions [Member]	Fiscal 2013 Actions [Member]	Other Operating Cost Reductions [Member]
				Restructuring [Member]	Restructuring [Member]	Restructuring [Member]	Restructuring [Member]	Restructuring [Member]		Restructuring [Member]	Restructuring [Member]	Restructuring [Member]	Restructuring [Member]	Restructuring [Member]		Restructuring [Member]	Restructuring [Member]	Restructuring [Member]	Restructuring [Member]	Restructuring [Member]
Restructuring Reserve [Roll Forward]	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Fiscal restructuring charges	'	'	$17.50	$14.80	$1.80	$0	$0	$0.90	$32.70	$14	$5.70	$0	$11.30	$1.70	$36.40	$2.30	$0.70	$21	$0.90	$11.50
Non-cash impairment charges	-33.3	-1.8	-0.6	-0.6	0	0	0	0	'	'	'	'	'	'	-3.1	0	0	0	0	-3.1
Stock-based compensation	'	'	-3.5	-3.5	0	0	0	0	-7.9	-6.3	0	0	-1.6	0	-6.5	0	0	-6.5	0	0
Severance payments	'	'	-2.6	-2.4	0	0	0	-0.2	-21.5	-13.1	-3.1	0	-4.4	-0.9	-24.4	-0.9	-4	-7.7	-5.9	-5.9
Other payments	'	'	-0.8	0	0	0	0	-0.8	-1.2	0	-0.6	0	0	-0.6	-0.5	0	-0.4	0	0	-0.1
Acquired and other	'	'	0.2	0.1	0	0	0	0.1	'	'	'	'	'	'	'	'	'	'	'	'
Balance	'	'	$10.20	$8.40	$1.80	$0	$0	$0	$12.30	$3	$3.80	$0	$5.30	$0.20	$14.20	$4.40	$0.10	$6.80	$0.30	$2.60

Restructuring_and_Divestiture_4

Restructuring and Divestiture Charges - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

In Millions, unless otherwise specified

Mar. 29, 2014

Dec. 28, 2013

Sep. 28, 2013

Mar. 30, 2013

Jun. 28, 2014

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Jun. 28, 2014

Jun. 29, 2013

Sep. 29, 2012

Jun. 28, 2014

Jun. 29, 2013

Jun. 28, 2014

Jun. 29, 2013

Sep. 28, 2013

Sep. 29, 2012

Sep. 28, 2013

Dec. 28, 2013

Jun. 29, 2013

Jun. 28, 2014

Jun. 29, 2013

Sep. 29, 2012

Sep. 28, 2013

Sep. 29, 2012

Dec. 28, 2013

Sep. 28, 2013

Jun. 28, 2014

Mar. 29, 2014

Dec. 28, 2013

Dec. 28, 2013

Sep. 28, 2013

Jun. 29, 2013

Jun. 28, 2014

Jun. 28, 2014

Mar. 29, 2014

Dec. 28, 2013

Jun. 29, 2013

Jun. 29, 2013

Sep. 28, 2013

Consolidation of Diagnostics Operations [Member]

Consolidation of Diagnostics Operations [Member]

Consolidation of Diagnostics Operations [Member]

Consolidation of Diagnostics Operations [Member]

Consolidation of Diagnostics Operations [Member]

Consolidation of Diagnostics Operations [Member]

Consolidation of Diagnostics Operations [Member]

Consolidation of Diagnostics Operations [Member]

Consolidation of Diagnostics Operations [Member]

Consolidation of Diagnostics Operations [Member]

Consolidation of Diagnostics Operations [Member]

Consolidation of Diagnostics Operations [Member]

Closure of Indianapolis Facility [Member]

Closure of Indianapolis Facility [Member]

Closure of Indianapolis Facility [Member]

Closure of Indianapolis Facility [Member]

Closure of Indianapolis Facility [Member]

Closure of Indianapolis Facility [Member]

Closure of Indianapolis Facility [Member]

Closure of Indianapolis Facility [Member]

Closure of Indianapolis Facility [Member]

Fiscal 2014 Actions [Member]

Fiscal 2014 Actions [Member]

Fiscal 2014 Actions [Member]

Fiscal 2014 Actions [Member]

Fiscal 2013 Actions [Member]

Fiscal 2013 Actions [Member]

Fiscal 2013 Actions [Member]

Other Operating Cost Reductions [Member]

Other Operating Cost Reductions [Member]

Other Operating Cost Reductions [Member]

One-time Termination Benefits [Member]

One-time Termination Benefits [Member]

One-time Termination Benefits [Member]

Molecular Diagnostics Operations [Member]

Molecular Diagnostics Operations [Member]

Molecular Diagnostics Operations [Member]

Molecular Diagnostics Operations [Member]

Molecular Diagnostics Operations [Member]

Molecular Diagnostics Operations [Member]

Restructuring [Member]

Indiana [Member ]

Indiana [Member ]

Restructuring [Member]

Restructuring [Member]

Jack Cumming [Member]

employee

Restructuring Cost and Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Severance charges

'

'

'

'

'

'

$0.30

'

$0

$10.80

$13.30

$0.60

$0.80

$2.30

$2.60

$3.20

$0.90

$10.80

$0.20

$1.40

$5.90

$4.50

$0.90

'

'

'

$4.80

$5

$3

$6.30

$6.60

$6.80

$3.60

$0.90

$1.10

$7.30

'

$0.40

$1

$1.10

Compensation charges

'

'

'

'

'

'

'

'

'

'

3.5

'

'

'

'

'

'

6.3

'

'

'

'

'

'

'

'

'

1.7

'

0.4

4.4

1.4

'

'

'

'

'

'

'

'

Employee retention program, payments in cash

'

'

'

'

'

'

'

9.7

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated aggregate severance charges

'

'

'

'

'

'

'

'

'

'

'

'

'

7.1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.4

'

'

'

9.2

'

'

'

Exiting charges

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.8

0.9

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of employees affected for severance benefits

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

95

'

'

'

Impairment charges of equipment fair value

'

3.1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.1

'

'

'

Impairment charges for assets held-for-sale

28.6

'

0.7

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assets held-for-sale, sales value

'

2.8

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other restructuring charges

'

'

'

'

0.2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assets held-for-sale, inventory and certain equipment

'

'

2.4

'

'

2.4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assets held-for-sale, goodwill

'

'

0.6

'

'

0.6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain on the sale of lifecodes business

'

'

'

0.9

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Disposition charge

'

'

'

'

'

$0.30

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Borrowings_and_Credit_Arrangem2

Borrowings and Credit Arrangements - Company's Borrowings (Detail) (USD $)	Jun. 28, 2014	Sep. 28, 2013
In Millions, unless otherwise specified
Debt Instrument [Line Items]	'	'
Current debt obligations, net of debt discount	$102	$563.80
Convertible Notes	0	400.1
Convertible Notes	1,223	1,188
Total long-term debt obligations	4,168.50	4,242.10
Total debt obligations	4,270.50	4,805.90
Term Loan A [Member]	'	'
Debt Instrument [Line Items]	'	'
Current debt obligations, net of debt discount	87.1	49.7
Long-term debt obligations, net of debt discount	821.2	894.8
Term Loan B [Member]	'	'
Debt Instrument [Line Items]	'	'
Current debt obligations, net of debt discount	14.9	114
Long-term debt obligations, net of debt discount	1,124.30	1,159.30
Senior Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt obligations, net of debt discount	$1,000	$1,000

Borrowings_and_Credit_Arrangem3

Borrowings and Credit Arrangements - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

Jun. 28, 2014

Jun. 29, 2013

Jun. 28, 2014

Jun. 29, 2013

Jun. 28, 2014

Mar. 29, 2014

Jun. 29, 2013

Jun. 28, 2014

Jun. 29, 2013

Jun. 28, 2014

Jun. 29, 2013

Jun. 28, 2014

Jun. 29, 2013

Feb. 26, 2014

Oct. 31, 2013

Dec. 28, 2013

Jun. 28, 2014

Feb. 26, 2014

Feb. 26, 2014

Feb. 26, 2014

Feb. 26, 2014

Feb. 26, 2014

Nov. 14, 2013

Nov. 14, 2013

Mar. 30, 2013

Jun. 28, 2014

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Term Loan B [Member]

Term Loan B [Member]

Term Loan B [Member]

Term Loan B [Member]

Term Loan B [Member]

Term Loan B [Member]

Term Loan B [Member]

Term Loan B [Member]

Term Loan B [Member]

2007 Notes [Member]

2007 Notes [Member]

Term Loan A [Member]

Term Loan A [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Base Rate Floor [Member]

Percentage Added to Base Rate [Member]

Eurodollar Rate Floor [Member]

Percentage Added to Eurodollar Rate [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Prepaid principal amount

'

'

'

'

'

'

'

'

'

'

'

'

'

$25,000,000

$100,000,000

'

'

'

'

'

'

'

'

'

'

'

Debt extinguishment loss

0

0

7,400,000

3,200,000

'

4,400,000

'

'

'

'

'

'

'

'

'

2,900,000

'

'

'

'

'

'

'

'

3,200,000

'

Issue price of principal amount, Term Loan B

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

99.88%

'

'

'

'

'

'

'

'

Debt Floor Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.75%

'

0.75%

'

'

'

'

'

Debt Instrument, Basis Spread on Variable Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.50%

'

2.50%

'

'

'

'

Basis point reduction in the interest rate on the New Term Loan B

'

'

'

'

'

'

'

'

'

'

'

'

'

0.50%

'

'

'

'

'

'

'

'

'

'

'

'

Refinancing issuance costs

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,400,000

'

Weighted average interest rates, Borrowings outstanding under the credit agreement

'

'

'

'

2.76%

'

'

2.93%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rates under Term Loans

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.25%

'

'

'

'

'

'

'

'

2.15%

Interest expense

'

'

'

'

17,900,000

'

26,100,000

57,500,000

84,700,000

16,000,000

16,000,000

48,000,000

48,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-cash interest expense amortization of debt discount and deferred financing costs

'

'

52,200,000

61,200,000

3,100,000

'

3,400,000

9,600,000

11,200,000

400,000

400,000

1,200,000

1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.00%

'

'

Senior note interest rate per year

'

'

'

'

'

'

'

'

'

'

'

6.25%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redemption price of notes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

Notes principal amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$405,000,000

'

'

Borrowings_and_Credit_Arrangem4

Borrowings and Credit Arrangements - Interest Expense under Convertible Notes (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013	Sep. 28, 2013
Debt Conversion [Line Items]	'	'	'	'	'
Non-cash interest expense	'	'	$52.20	$61.20	'
Convertible Notes Payable [Member]	'	'	'	'	'
Debt Conversion [Line Items]	'	'	'	'	'
Amortization of debt discount	8.5	11.6	28.4	40.9	'
Amortization of deferred financing costs	0.4	0.7	1.5	2.4	'
Principal accretion	3.9	3.7	11.4	5.5	'
Non-cash interest expense	12.8	16	41.3	48.8	'
2.00% accrued interest	4.7	8.6	17.6	25.8	'
Interest expense, net	$17.50	$24.60	$58.90	$74.60	'
Percentage of accrued interest on Convertible Notes	2.00%	'	2.00%	'	2.00%

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

In Millions, unless otherwise specified

Oct. 29, 2013

Jun. 28, 2014

Jun. 29, 2013

Jun. 28, 2014

Jun. 29, 2013

Sep. 04, 2012

Dec. 29, 2012

Dec. 29, 2012

Mar. 30, 2013

Jun. 28, 2014

Jun. 30, 2011

Dec. 28, 2013

Sep. 28, 2013

Adiana, Inc. [Member]

Sentinelle Medical Inc. [Member]

Interlace Business. [Member]

Interlace Business. [Member]

TCT International Co., Ltd. [Member]

TCT International Co., Ltd. [Member]

TCT International Co., Ltd. [Member]

Contingent Consideration Earn-Out Payments [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Payment of contingent consideration

'

'

'

$0

$42.40

'

$16.80

$3.40

$86.90

'

'

$31.10

$87.40

Contingent payments period

'

'

'

'

'

'

'

'

'

'2 years

'2 years

'

'

Contingent consideration – fair value adjustments

'

'

'

'

'

'

'

'

93.8

'

'

'

'

Accrued contingent payments

'

'

'

'

'

'

'

'

'

3.1

'

'

'

Contingent consideration – compensation expense

'

0

21.6

0

80.5

'

'

'

'

'

'

'

'

Assessed damages

'

'

'

'

'

4

'

'

'

'

'

'

'

Additional Payments

$14.70

'

'

'

'

'

'

'

'

'

'

'

'

Commitments_and_Contingencies_2

Commitments and Contingencies - Summary of Contingent Consideration Charges Recorded to the Consolidated Statement of Operations (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Other Contingencies And Commitments [Line Items]	'	'	'	'
Contingent consideration – compensation expense	$0	$21.60	$0	$80.50
Contingent consideration – fair value adjustments	0	0.5	0	11.3
Contingent consideration total	'	22.1	'	91.8
Interlace Medical, Inc. [Member]	'	'	'	'
Other Contingencies And Commitments [Line Items]	'	'	'	'
Contingent consideration – compensation expense	'	0	'	0
Contingent consideration – fair value adjustments	'	0.5	'	11.3
Contingent consideration total	'	0.5	'	11.3
TCT International Co., Ltd. [Member]	'	'	'	'
Other Contingencies And Commitments [Line Items]	'	'	'	'
Contingent consideration – compensation expense	'	21.6	'	80.5
Contingent consideration – fair value adjustments	'	0	'	0
Contingent consideration total	'	$21.60	'	$80.50

Sale_of_Makena_Additional_Info

Sale of Makena - Additional Information (Detail) (USD $)	3 Months Ended			9 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Dec. 29, 2012	Jun. 28, 2014	Jun. 29, 2013
Regulatory Assets [Abstract]	'	'	'	'	'
Amended transaction price as a result of executing amendment	'	'	'	$199.50	'
Final payment received	'	'	60	'	'
Gain on net of certain contingent legal fees and amounts due to inventory	$0	$0	$53.90	$0	$53.90

Marketable_Securities_Reconcil

Marketable Securities - Reconciles Cost Basis to Fair Market Value of Company's Equity Security (Detail) (Equity Security [Member], USD $)	Jun. 28, 2014	Sep. 28, 2013
In Millions, unless otherwise specified
Equity Security [Member]	'	'
Schedule Of Marketable Securities [Line Items]	'	'
Equity security, Cost	$5.90	$5.90
Equity security, Gross Unrealized Gains	14.1	12.2
Equity security, Gross Unrealized Losses	0	0
Equity security, Fair Value	$20	$18.10

Net_Income_Loss_Per_Share_Reco

Net Income (Loss) Per Share - Reconciliation of Basic and Diluted Share Amounts (Detail)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Earnings Per Share [Line Items]	'	'	'	'
Basic weighted average common shares outstanding (in shares)	276,843	269,430	274,713	267,983
Weighted average common stock equivalents from assumed exercise of stock options and restricted stock units (in shares)	2,130	0	0	0
Incremental Common Shares Attributable To The Conversion Of Debt Securities	232	0	0	0
Diluted weighted average common shares outstanding (in shares)	279,205	269,430	274,713	267,983
Outstanding Stock Options [Member]	'	'	'	'
Weighted-average anti-dilutive shares related to:	'	'	'	'
Weighted-average anti-dilutive shares	4,727	7,964	7,007	8,724
Restricted Stock Units [Member]	'	'	'	'
Weighted-average anti-dilutive shares related to:	'	'	'	'
Weighted-average anti-dilutive shares	21	1,147	811	1,089

StockBased_Compensation_StockB

Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expense	$13	$10.80	$39.10	$41.90
Cost of Revenues [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expense	1.9	1.7	5.5	5.2
Research and Development [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expense	2.2	1.7	6.3	5.6
Selling and Marketing [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expense	2	2.2	6.1	7
General and Administrative [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expense	5.2	4.7	14.7	16.4
Restructuring [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expense	$1.70	$0.50	$6.50	$7.70

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	1 Months Ended	9 Months Ended		3 Months Ended	1 Months Ended	9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013	Jun. 28, 2014	Jun. 29, 2013	Dec. 28, 2013	Dec. 31, 2013	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014
	tranche			Performance Shares [Member]	Restricted Stock Units [Member]	Restricted Stock Units [Member]	Restricted Stock Units [Member]	Stock Option Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'
Options granted	'	2.4	2.3	'	'	'	'	'
Weighted-average exercise prices	'	$21.92	$19.95	'	'	'	'	'
Share-based compensation, stock option outstanding	'	9.9	'	'	'	'	'	'
Weighted-average exercise price of options outstanding	'	$20.31	'	'	'	'	'	'
Restricted stock units	'	'	'	0.4	'	2.4	2	'
Restricted stock units (RSUs), weighted average grant date fair values	'	'	'	$21.77	'	$21.97	$19.86	'
Unvested RSUs outstanding	'	'	'	'	'	4.2	'	'
Unvested RSUs weighted-average grant date fair value	'	'	'	'	'	$20.61	'	'
Performance stock units	'	'	'	0.4	'	2.4	2	'
Performance stock units (PSUs), weighted average grant date fair values	'	'	'	$21.77	'	$21.97	$19.86	'
Minimum eligible percentage to receive target number of shares of company's common stock	'	'	'	0.00%	'	'	'	'
Maximum eligible percentage to receive target number of shares of company's common stock	'	'	'	200.00%	'	'	'	'
Performance stock units vesting period	'	'	'	'3 years	'3 years	'	'	'
Market stock units granted during the period	0.1	'	'	'	'	'	'	'
Valuation of MSUs using Monte Carlo simulation model	$18.65	'	'	'	'	'	'	'
Number of separate tranches	3	'	'	'	'	'	'	'
Trading period considered for determination of average price of stock for stock based award	'30 days	'	'	'	'	'	'	'
Restricted stock units	0.2	'	'	'	'	'	'	'
Purchase of common stock from open market	0.2	'	'	'	'	'	'	'
Restricted stock units vesting period	'	'	'	'3 years	'3 years	'	'	'
Unrecognized compensation expense	'	'	'	'	'	$72.80	'	$26.90
Weighted-average period for recognition of unrecognized stock-based compensation, years	'	'	'	'	'	'2 years 9 months 18 days	'	'3 years 1 month 6 days

StockBased_Compensation_Weight

Stock-Based Compensation - Weighted-Average Assumptions Utilized to Value Stock Options (Detail) (Employee Stock Purchase Plan [Member], USD $)	3 Months Ended		9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Employee Stock Purchase Plan [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Risk-free interest rate	1.30%	0.50%	1.20%	0.50%
Expected volatility	41.40%	43.70%	'	43.70%
Expected life (in years)	'4 years 5 months 24 days	'4 years 4 months 24 days	'4 years 4 months 24 days	'4 years 4 months 24 days
Dividend yield	$0	$0	$0	$0
Weighted average fair value of options granted	$7.97	$7.47	$7.64	$7.09

Other_Balance_Sheet_Informatio2

Other Balance Sheet Information - Other Balance Sheet Information of Inventories (Detail) (USD $)	Jun. 28, 2014	Sep. 28, 2013
In Millions, unless otherwise specified
Other Balance Sheet Information [Abstract]	'	'
Raw materials	$121	$115.60
Work-in-process	59	51.2
Finished goods	149.8	122.6
Inventories	$329.80	$289.40

Other_Balance_Sheet_Informatio3

Other Balance Sheet Information - Other Balance Sheet Information of Property, Plant and Equipment (Detail) (USD $)	Jun. 28, 2014	Sep. 28, 2013
In Millions, unless otherwise specified
Other Balance Sheet Information [Abstract]	'	'
Equipment and software	$341.60	$318.50
Equipment under customer usage agreements	285.3	275.7
Building and improvements	175.6	171.5
Leasehold improvements	64.1	68.2
Land	51.7	51.6
Furniture and fixtures	16.3	22.5
Property, plant and equipment, gross	934.6	908
Less – accumulated depreciation and amortization	-467.2	-416.5
Property, plant and equipment, net	$467.40	$491.50

Business_Segments_and_Geograph2

Business Segments and Geographic Information - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013	Sep. 28, 2013
	Customer	Customer	Segment	Customer	Customer
			Customer
Segment Reporting Disclosure [Line Items]	'	'	'	'	'
Number of reportable segments	'	'	4	'	'
Revenues	$632.60	$626.10	$1,870.10	$1,870.20	'
Customers with balances greater than 10% of accounts receivable	0	'	0	'	0
Customer represented greater than 10% of consolidated revenues	0	0	0	0	'
Intersegment [Member]	'	'	'	'	'
Segment Reporting Disclosure [Line Items]	'	'	'	'	'
Revenues	$0	$0	$0	$0	'

Business_Segments_and_Geograph3

Business Segments and Geographic Information - Segment Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013	Sep. 28, 2013
Segment Reporting Information [Line Items]	'	'	'	'	'
Total revenues	$632.60	$626.10	$1,870.10	$1,870.20	'
Operating income (loss)	76.2	61.1	187.7	129.9	'
Depreciation and amortization	134	128.9	391.8	383.4	'
Capital expenditures	20	26.2	57.8	73	'
Identifiable assets	8,412	'	8,412	'	9,000.80
Diagnostics [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Total revenues	293.1	297.4	869.7	899.8	'
Operating income (loss)	4.8	-1.2	24.8	-33.7	'
Depreciation and amortization	95.8	92.2	282.6	273.2	'
Capital expenditures	12.8	13.4	37.9	40.6	'
Identifiable assets	4,468.60	'	4,468.60	'	4,667.90
Breast Health [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Total revenues	238	230	703.2	671	'
Operating income (loss)	58.4	53.2	128	146	'
Depreciation and amortization	11.7	10	30.2	30.1	'
Capital expenditures	2.7	4.2	6.8	13.7	'
Identifiable assets	882.8	'	882.8	'	932.2
GYN Surgical [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Total revenues	78.5	75.8	229.4	230.4	'
Operating income (loss)	9.1	6.3	26.8	9.1	'
Depreciation and amortization	26.3	26.5	78.4	79.5	'
Capital expenditures	2	2.4	5.9	7.4	'
Identifiable assets	1,770.90	'	1,770.90	'	1,849.50
Skeletal Health [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Total revenues	23	22.9	67.8	69	'
Operating income (loss)	3.9	2.8	8.1	8.5	'
Depreciation and amortization	0.2	0.2	0.6	0.6	'
Capital expenditures	0	0.2	0.2	0.4	'
Identifiable assets	25.5	'	25.5	'	33.5
Corporate [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Capital expenditures	2.5	6	7	10.9	'
Identifiable assets	$1,264.20	'	$1,264.20	'	$1,517.70

Business_Segments_and_Geograph4

Business Segments and Geographic Information - Revenues by Geography (Detail)	3 Months Ended		9 Months Ended
	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Schedule Of Geographical Segments [Line Items]	'	'	'	'
Revenues	100.00%	100.00%	100.00%	100.00%
United States [Member]	'	'	'	'
Schedule Of Geographical Segments [Line Items]	'	'	'	'
Revenues	76.00%	75.00%	75.00%	74.00%
Europe [Member]	'	'	'	'
Schedule Of Geographical Segments [Line Items]	'	'	'	'
Revenues	12.00%	13.00%	14.00%	14.00%
Asia-Pacific [Member]	'	'	'	'
Schedule Of Geographical Segments [Line Items]	'	'	'	'
Revenues	8.00%	8.00%	7.00%	8.00%
All Others [Member]	'	'	'	'
Schedule Of Geographical Segments [Line Items]	'	'	'	'
Revenues	4.00%	4.00%	4.00%	4.00%

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Income Tax Disclosure [Abstract]	'	'	'	'
Company's effective tax rate	50.00%	-58.20%	214.20%	33.00%
Valuation allowance	$19.60	'	$19.60	'

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets - Rollforward of Goodwill Activity by Reportable Segment (Detail) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014
Goodwill [Roll Forward]	'
Balance at September 28, 2013	$2,814.50
Disposition of a portion of a reporting unit	-0.2
Tax adjustments	-0.6
Foreign currency and other	-2.6
Balance at June 28, 2014	2,811.10
Diagnostics [Member]	'
Goodwill [Roll Forward]	'
Balance at September 28, 2013	1,153.50
Disposition of a portion of a reporting unit	-0.2
Tax adjustments	-0.6
Foreign currency and other	-0.6
Balance at June 28, 2014	1,152.10
Breast Health [Member]	'
Goodwill [Roll Forward]	'
Balance at September 28, 2013	636.4
Disposition of a portion of a reporting unit	0
Tax adjustments	0
Foreign currency and other	-1.7
Balance at June 28, 2014	634.7
GYN Surgical [Member]	'
Goodwill [Roll Forward]	'
Balance at September 28, 2013	1,016.40
Disposition of a portion of a reporting unit	0
Tax adjustments	0
Foreign currency and other	-0.3
Balance at June 28, 2014	1,016.10
Skeletal Health [Member]	'
Goodwill [Roll Forward]	'
Balance at September 28, 2013	8.2
Disposition of a portion of a reporting unit	0
Tax adjustments	0
Foreign currency and other	0
Balance at June 28, 2014	$8.20

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets - Schedule of Intangible Assets (Detail) (USD $)	Jun. 28, 2014	Sep. 28, 2013
In Millions, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	$5,348.30	$5,388.60
Accumulated Amortization	1,789.60	1,481.90
Developed Technology [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	3,969.90	4,009
Accumulated Amortization	1,317.60	1,094.50
In-process Research and Development [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	23	24
Accumulated Amortization	0	0
Customer Relationships and Contracts [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	1,101.90	1,101.90
Accumulated Amortization	362.5	296.5
Trade Names [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	236.8	238.1
Accumulated Amortization	98.8	81.8
Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	14.1	13
Accumulated Amortization	8.8	8.5
Business Licenses [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	2.6	2.6
Accumulated Amortization	$1.90	$0.60

Goodwill_and_Intangible_Assets4

Goodwill and Intangible Assets - Additional Information (Detail) (USD $)	3 Months Ended			9 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Mar. 29, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Impairment charges	'	$27.10	'	'	'
Impairment of intangible assets	0	'	1.7	26.6	1.7
Developed Technology [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Impairment charges	'	26.6	'	'	'
Impairment of intangible assets	'	'	'	'	1.7
Trade Names [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Impairment charges	'	$0.50	'	'	'

Goodwill_and_Intangible_Assets5

Goodwill and Intangible Assets - Schedule of Estimated Amortization Expense (Detail) (USD $)	Jun. 28, 2014
In Millions, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]	'
Remainder of Fiscal 2014	$109.50
Fiscal 2015	414.6
Fiscal 2016	374.5
Fiscal 2017	365.4
Fiscal 2018	$354.90

Product_Warranties_Product_War

Product Warranties - Product Warranty (Detail) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]	'	'
Balance at Beginning of Period	$9.30	$6.20
Provisions	5.5	8.8
Settlements/ Adjustments	-7.5	-7.2
Balance at End of Period	$7.30	$7.80

Supplemental_Guarantor_Condens2

Supplemental Guarantor Condensed Consolidating Financials - Additional Information (Detail) (Parent/Issuer [Member])	9 Months Ended
	Jun. 28, 2014
Parent/Issuer [Member]	'
Condensed Financial Statements, Captions [Line Items]	'
Ownership percentage in domestic subsidiaries	100.00%

Supplemental_Guarantor_Condens3

Supplemental Guarantor Condensed Consolidating Financials - Schedule of Supplemental Condensed Consolidating Statement of Operations (Detail) (USD $)	3 Months Ended			9 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Dec. 29, 2012	Jun. 28, 2014	Jun. 29, 2013
Revenues:	'	'	'	'	'
Product	$529.30	$529.90	'	$1,562.80	$1,579.30
Service and other	103.3	96.2	'	307.3	290.9
Revenues	632.6	626.1	'	1,870.10	1,870.20
Costs of revenues:	'	'	'	'	'
Product	186.7	187.6	'	549.3	617.2
Amortization of intangible assets	80.5	76	'	234.1	227
Impairment of intangible assets	0	1.7	'	26.6	1.7
Service and other	52.6	51	'	159.6	153.5
Gross Profit	312.8	309.8	'	900.5	870.8
Operating expenses:	'	'	'	'	'
Research and development	52.5	47.8	'	151.1	148.9
Selling and marketing	83	82.9	'	245	265.4
General and administrative	64.7	60.5	'	194.6	179.7
Amortization of intangible assets	29.7	28.7	'	85	85.9
Contingent consideration – compensation expense	0	21.6	'	0	80.5
Impairment of intangible assets	0	0	'	0.5	0
Contingent consideration – fair value adjustments	0	0.5	'	0	11.3
Gain on sale of intellectual property	0	0	-53.9	0	-53.9
Restructuring and divestiture charges	6.7	6.7	'	36.6	23.1
Operating expenses	236.6	248.7	'	712.8	740.9
Income from operations	76.2	61.1	'	187.7	129.9
Interest income	0.3	0.3	'	0.8	0.8
Interest expense	-52.4	-67.2	'	-168.1	-215.3
Debt extinguishment loss	0	0	'	-7.4	-3.2
Other expense, net	-1.5	-1.2	'	-3.5	-0.2
Income (loss) before income taxes	22.6	-7	'	9.5	-88
Provision (benefit) for income taxes	11.3	4	'	20.3	-29.1
Equity in earnings (losses) of subsidiaries	0	0	'	0	0
Net income (loss)	11.3	-11	'	-10.8	-58.9
Eliminations [Member]	'	'	'	'	'
Revenues:	'	'	'	'	'
Product	-111.3	-90.5	'	-321.7	-268.9
Service and other	-12.4	-12.4	'	-40	-40.7
Revenues	-123.7	-102.9	'	-361.7	-309.6
Costs of revenues:	'	'	'	'	'
Product	-111.3	-90.5	'	-321.7	-268.9
Amortization of intangible assets	0	0	'	0	0
Impairment of intangible assets	'	0	'	0	0
Service and other	-12.4	-12.4	'	-40	-40.7
Gross Profit	0	0	'	0	0
Operating expenses:	'	'	'	'	'
Research and development	0	0	'	0	0
Selling and marketing	0	0	'	0	0
General and administrative	0	0	'	0	0
Amortization of intangible assets	0	0	'	0	0
Contingent consideration – compensation expense	'	0	'	'	0
Impairment of intangible assets	'	'	'	0	'
Contingent consideration – fair value adjustments	'	0	'	'	0
Gain on sale of intellectual property	'	'	'	'	0
Restructuring and divestiture charges	0	0	'	0	0
Operating expenses	0	0	'	0	0
Income from operations	0	0	'	0	0
Interest income	-1.1	0	'	-2.5	0
Interest expense	1.1	0	'	2.5	0
Debt extinguishment loss	'	'	'	0	0
Other expense, net	0	0	'	0	0
Income (loss) before income taxes	0	0	'	0	0
Provision (benefit) for income taxes	0	0	'	0	0
Equity in earnings (losses) of subsidiaries	-7.6	91.3	'	-4.2	15.4
Net income (loss)	-7.6	91.3	'	-4.2	15.4
Parent/Issuer [Member]	'	'	'	'	'
Revenues:	'	'	'	'	'
Product	128.4	106.5	'	356.8	305.2
Service and other	88.2	81.4	'	262.7	240.5
Revenues	216.6	187.9	'	619.5	545.7
Costs of revenues:	'	'	'	'	'
Product	61.5	57.7	'	172.4	163.7
Amortization of intangible assets	1.4	1.3	'	4.2	4
Impairment of intangible assets	'	0	'	0	0
Service and other	46.8	39.1	'	140.3	118.1
Gross Profit	106.9	89.8	'	302.6	259.9
Operating expenses:	'	'	'	'	'
Research and development	7.7	8	'	23	22.7
Selling and marketing	16.8	17.9	'	52.6	59.1
General and administrative	15.8	20	'	45.5	52
Amortization of intangible assets	0.6	0.8	'	2.4	2.2
Contingent consideration – compensation expense	'	21.6	'	'	80.5
Impairment of intangible assets	'	'	'	0	'
Contingent consideration – fair value adjustments	'	0.5	'	'	11.3
Gain on sale of intellectual property	'	'	'	'	0
Restructuring and divestiture charges	1	0.6	'	7.6	0.9
Operating expenses	41.9	69.4	'	131.1	228.7
Income from operations	65	20.4	'	171.5	31.2
Interest income	0.1	0.1	'	0.3	0.4
Interest expense	-52.6	-66.3	'	-168	-212.9
Debt extinguishment loss	'	'	'	-7.4	-3.2
Other expense, net	1.3	178.1	'	7.9	179.8
Income (loss) before income taxes	13.8	132.3	'	4.3	-4.7
Provision (benefit) for income taxes	6.8	50.9	'	5	24.3
Equity in earnings (losses) of subsidiaries	4.3	-92.4	'	-10.1	-29.9
Net income (loss)	11.3	-11	'	-10.8	-58.9
Guarantor Subsidiaries [Member]	'	'	'	'	'
Revenues:	'	'	'	'	'
Product	386.4	399.1	'	1,154	1,177.70
Service and other	14.4	15.9	'	47.4	56.5
Revenues	400.8	415	'	1,201.40	1,234.20
Costs of revenues:	'	'	'	'	'
Product	147.3	143.8	'	431.7	478.1
Amortization of intangible assets	75.3	73.7	'	224	219.8
Impairment of intangible assets	'	0	'	0	0
Service and other	5.9	14.8	'	27.5	46.2
Gross Profit	172.3	182.7	'	518.2	490.1
Operating expenses:	'	'	'	'	'
Research and development	42.9	37.2	'	121.7	118.8
Selling and marketing	43.4	43.5	'	126.8	136.2
General and administrative	37.8	31.3	'	114.9	101
Amortization of intangible assets	26.8	26.7	'	77.9	80.1
Contingent consideration – compensation expense	'	0	'	'	0
Impairment of intangible assets	'	'	'	0	'
Contingent consideration – fair value adjustments	'	0	'	'	0
Gain on sale of intellectual property	'	'	'	'	-53.9
Restructuring and divestiture charges	2.9	3.7	'	15	17.7
Operating expenses	153.8	142.4	'	456.3	399.9
Income from operations	18.5	40.3	'	61.9	90.2
Interest income	1.1	0	'	2.3	0.1
Interest expense	-0.3	-0.3	'	-0.8	-0.9
Debt extinguishment loss	'	'	'	0	0
Other expense, net	-3	-179.2	'	-12.4	-186.3
Income (loss) before income taxes	16.3	-139.2	'	51	-96.9
Provision (benefit) for income taxes	3.6	-49.9	'	9.9	-61.1
Equity in earnings (losses) of subsidiaries	3.3	1.1	'	14.3	14.5
Net income (loss)	16	-88.2	'	55.4	-21.3
Non-Guarantor Subsidiaries [Member]	'	'	'	'	'
Revenues:	'	'	'	'	'
Product	125.8	114.8	'	373.7	365.3
Service and other	13.1	11.3	'	37.2	34.6
Revenues	138.9	126.1	'	410.9	399.9
Costs of revenues:	'	'	'	'	'
Product	89.2	76.6	'	266.9	244.3
Amortization of intangible assets	3.8	1	'	5.9	3.2
Impairment of intangible assets	'	1.7	'	26.6	1.7
Service and other	12.3	9.5	'	31.8	29.9
Gross Profit	33.6	37.3	'	79.7	120.8
Operating expenses:	'	'	'	'	'
Research and development	1.9	2.6	'	6.4	7.4
Selling and marketing	22.8	21.5	'	65.6	70.1
General and administrative	11.1	9.2	'	34.2	26.7
Amortization of intangible assets	2.3	1.2	'	4.7	3.6
Contingent consideration – compensation expense	'	0	'	'	0
Impairment of intangible assets	'	'	'	0.5	'
Contingent consideration – fair value adjustments	'	0	'	'	0
Gain on sale of intellectual property	'	'	'	'	0
Restructuring and divestiture charges	2.8	2.4	'	14	4.5
Operating expenses	40.9	36.9	'	125.4	112.3
Income from operations	-7.3	0.4	'	-45.7	8.5
Interest income	0.2	0.2	'	0.7	0.3
Interest expense	-0.6	-0.6	'	-1.8	-1.5
Debt extinguishment loss	'	'	'	0	0
Other expense, net	0.2	-0.1	'	1	6.3
Income (loss) before income taxes	-7.5	-0.1	'	-45.8	13.6
Provision (benefit) for income taxes	0.9	3	'	5.4	7.7
Equity in earnings (losses) of subsidiaries	0	0	'	0	0
Net income (loss)	($8.40)	($3.10)	'	($51.20)	$5.90

Supplemental_Guarantor_Condens4

Supplemental Guarantor Condensed Consolidating Financials - Schedule of Supplemental Condensed Consolidating Statements of Comprehensive (Loss) Income (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013	Jun. 28, 2014	Jun. 29, 2013
Condensed Financial Statements, Captions [Line Items]	'	'	'	'
Net income (loss)	$11.30	($11)	($10.80)	($58.90)
Changes in foreign currency translation adjustment	3.3	-2.9	-3.7	-9.3
Changes in unrealized holding gains on available-for-sale securities	4.2	0.1	1.9	2.3
Changes in pension plans, net of taxes	0	0	-0.6	0
Comprehensive income (loss)	18.8	-13.8	-13.2	-65.9
Eliminations [Member]	'	'	'	'
Condensed Financial Statements, Captions [Line Items]	'	'	'	'
Net income (loss)	-7.6	91.3	-4.2	15.4
Changes in foreign currency translation adjustment	0	0	0	0
Changes in unrealized holding gains on available-for-sale securities	0	0	0	0
Changes in pension plans, net of taxes	'	'	0	'
Comprehensive income (loss)	-7.6	91.3	-4.2	15.4
Parent/Issuer [Member]	'	'	'	'
Condensed Financial Statements, Captions [Line Items]	'	'	'	'
Net income (loss)	11.3	-11	-10.8	-58.9
Changes in foreign currency translation adjustment	0	0	0	0
Changes in unrealized holding gains on available-for-sale securities	0	0	0	0
Changes in pension plans, net of taxes	'	'	0	'
Comprehensive income (loss)	11.3	-11	-10.8	-58.9
Guarantor Subsidiaries [Member]	'	'	'	'
Condensed Financial Statements, Captions [Line Items]	'	'	'	'
Net income (loss)	16	-88.2	55.4	-21.3
Changes in foreign currency translation adjustment	0.3	0	0.4	0.2
Changes in unrealized holding gains on available-for-sale securities	4.2	0.1	1.9	2.3
Changes in pension plans, net of taxes	'	'	0	'
Comprehensive income (loss)	20.5	-88.1	57.7	-18.8
Non-Guarantor Subsidiaries [Member]	'	'	'	'
Condensed Financial Statements, Captions [Line Items]	'	'	'	'
Net income (loss)	-8.4	-3.1	-51.2	5.9
Changes in foreign currency translation adjustment	3	-2.9	-4.1	-9.5
Changes in unrealized holding gains on available-for-sale securities	0	0	0	0
Changes in pension plans, net of taxes	'	'	-0.6	'
Comprehensive income (loss)	($5.40)	($6)	($55.90)	($3.60)

Supplemental_Guarantor_Condens5

Supplemental Guarantor Condensed Consolidating Financials - Schedule of Supplemental Condensed Consolidating Balance Sheet (Detail) (USD $)	Jun. 28, 2014	Sep. 28, 2013	Jun. 29, 2013	Sep. 29, 2012
In Millions, unless otherwise specified
Current assets:	'	'	'	'
Cash and cash equivalents	$632.50	$822.50	$958.40	$560.40
Restricted cash	5.9	6.9	'	'
Accounts receivable, net	381.7	409.3	'	'
Inventories	329.8	289.4	'	'
Deferred income tax assets	34.4	0	'	'
Prepaid income taxes	10.3	44.7	'	'
Prepaid expenses and other current assets	37.8	48.4	'	'
Intercompany receivables	'	0	'	'
Other current assets – assets held-for-sale	0	3	'	'
Total current assets	1,432.40	1,624.20	'	'
Property, plant and equipment, net	467.4	491.5	'	'
Intangible assets, net	3,558.70	3,906.70	'	'
Goodwill	2,811.10	2,814.50	'	'
Other assets	142.4	163.9	'	'
Long term intercompany receivables	0	'	'	'
Investment in subsidiaries	0	0	'	'
Total assets	8,412	9,000.80	'	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	102	563.8	'	'
Accounts payable	82.3	80.5	'	'
Accrued expenses	266.5	272	'	'
Deferred revenue	147.1	132.3	'	'
Deferred income tax liabilities	0	39.8	'	'
Intercompany payables	0	0	'	'
Total current liabilities	597.9	1,088.40	'	'
Long-term debt, net of current portion	4,168.50	4,242.10	'	'
Deferred income tax liabilities	1,410.80	1,535.30	'	'
Deferred service obligations – long-term	21.8	25.5	'	'
Long-term intercompany payables	0	'	'	'
Other long-term liabilities	181.7	168	'	'
Total stockholders’ equity	2,031.30	1,941.50	'	'
Total liabilities and stockholders’ equity	8,412	9,000.80	'	'
Eliminations [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	0	0	0	0
Restricted cash	0	0	'	'
Accounts receivable, net	0	0	'	'
Inventories	0	0	'	'
Deferred income tax assets	0	-19.5	'	'
Prepaid income taxes	0	-4.7	'	'
Prepaid expenses and other current assets	0	0	'	'
Intercompany receivables	-2,677	-2,474.50	'	'
Other current assets – assets held-for-sale	'	0	'	'
Total current assets	-2,677	-2,498.70	'	'
Property, plant and equipment, net	0	0	'	'
Intangible assets, net	0	0	'	'
Goodwill	0	0	'	'
Other assets	0	0	'	'
Long term intercompany receivables	-144	'	'	'
Investment in subsidiaries	-8,901.50	-8,798.90	'	'
Total assets	-11,722.50	-11,297.60	'	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	0	0	'	'
Accounts payable	0	0	'	'
Accrued expenses	0	-5	'	'
Deferred revenue	0	0	'	'
Deferred income tax liabilities	0	-19.5	'	'
Intercompany payables	-2,680	-2,482.50	'	'
Total current liabilities	-2,680	-2,507	'	'
Long-term debt, net of current portion	0	0	'	'
Deferred income tax liabilities	0	0	'	'
Deferred service obligations – long-term	0	-2.2	'	'
Long-term intercompany payables	-144	'	'	'
Other long-term liabilities	0	0	'	'
Total stockholders’ equity	-8,898.50	-8,788.40	'	'
Total liabilities and stockholders’ equity	-11,722.50	-11,297.60	'	'
Parent/Issuer [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	215.4	321.6	329.2	210
Restricted cash	0	0	'	'
Accounts receivable, net	114.3	126.1	'	'
Inventories	88.8	81.9	'	'
Deferred income tax assets	14.4	0	'	'
Prepaid income taxes	6	47.1	'	'
Prepaid expenses and other current assets	18.7	16.3	'	'
Intercompany receivables	0	0	'	'
Other current assets – assets held-for-sale	'	0	'	'
Total current assets	457.6	593	'	'
Property, plant and equipment, net	29.2	29.3	'	'
Intangible assets, net	14.1	19.9	'	'
Goodwill	282.4	283	'	'
Other assets	92.1	103.6	'	'
Long term intercompany receivables	0	'	'	'
Investment in subsidiaries	8,681	8,667.60	'	'
Total assets	9,556.40	9,696.40	'	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	102	563.8	'	'
Accounts payable	24	27.9	'	'
Accrued expenses	145.2	153	'	'
Deferred revenue	108.5	93.3	'	'
Deferred income tax liabilities	0	59.3	'	'
Intercompany payables	2,628.50	2,418.10	'	'
Total current liabilities	3,008.20	3,315.40	'	'
Long-term debt, net of current portion	4,168.50	4,242.10	'	'
Deferred income tax liabilities	82.6	89.1	'	'
Deferred service obligations – long-term	8.1	11.3	'	'
Long-term intercompany payables	144	'	'	'
Other long-term liabilities	113.7	97	'	'
Total stockholders’ equity	2,031.30	1,941.50	'	'
Total liabilities and stockholders’ equity	9,556.40	9,696.40	'	'
Guarantor Subsidiaries [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	272.6	387.4	516.8	269.4
Restricted cash	0	0	'	'
Accounts receivable, net	168.7	174.4	'	'
Inventories	186.1	146.7	'	'
Deferred income tax assets	19.2	19	'	'
Prepaid income taxes	2.9	2.3	'	'
Prepaid expenses and other current assets	10.1	21.1	'	'
Intercompany receivables	2,663.60	2,442.60	'	'
Other current assets – assets held-for-sale	'	0	'	'
Total current assets	3,323.20	3,193.50	'	'
Property, plant and equipment, net	338	356.7	'	'
Intangible assets, net	3,484.20	3,785	'	'
Goodwill	2,391	2,390.90	'	'
Other assets	48.5	58.4	'	'
Long term intercompany receivables	144	'	'	'
Investment in subsidiaries	220.3	129	'	'
Total assets	9,949.20	9,913.50	'	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	0	0	'	'
Accounts payable	46.2	42.6	'	'
Accrued expenses	71.2	79.6	'	'
Deferred revenue	7.9	8	'	'
Deferred income tax liabilities	0	0	'	'
Intercompany payables	0	0	'	'
Total current liabilities	125.3	130.2	'	'
Long-term debt, net of current portion	0	0	'	'
Deferred income tax liabilities	1,320.10	1,435.50	'	'
Deferred service obligations – long-term	4	3.5	'	'
Long-term intercompany payables	0	'	'	'
Other long-term liabilities	32.8	37.6	'	'
Total stockholders’ equity	8,467	8,306.70	'	'
Total liabilities and stockholders’ equity	9,949.20	9,913.50	'	'
Non-Guarantor Subsidiaries [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	144.5	113.5	112.4	81
Restricted cash	5.9	6.9	'	'
Accounts receivable, net	98.7	108.8	'	'
Inventories	54.9	60.8	'	'
Deferred income tax assets	0.8	0.5	'	'
Prepaid income taxes	1.4	0	'	'
Prepaid expenses and other current assets	9	11	'	'
Intercompany receivables	13.4	31.9	'	'
Other current assets – assets held-for-sale	'	3	'	'
Total current assets	328.6	336.4	'	'
Property, plant and equipment, net	100.2	105.5	'	'
Intangible assets, net	60.4	101.8	'	'
Goodwill	137.7	140.6	'	'
Other assets	1.8	1.9	'	'
Long term intercompany receivables	0	'	'	'
Investment in subsidiaries	0.2	2.3	'	'
Total assets	628.9	688.5	'	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	0	0	'	'
Accounts payable	12.1	10	'	'
Accrued expenses	50.1	44.4	'	'
Deferred revenue	30.7	31	'	'
Deferred income tax liabilities	0	0	'	'
Intercompany payables	51.5	64.4	'	'
Total current liabilities	144.4	149.8	'	'
Long-term debt, net of current portion	0	0	'	'
Deferred income tax liabilities	8.1	10.7	'	'
Deferred service obligations – long-term	9.7	12.9	'	'
Long-term intercompany payables	0	'	'	'
Other long-term liabilities	35.2	33.4	'	'
Total stockholders’ equity	431.5	481.7	'	'
Total liabilities and stockholders’ equity	$628.90	$688.50	'	'

Supplemental_Guarantor_Condens6

Supplemental Guarantor Condensed Consolidating Financials - Schedule of Consolidating Statement of Cash Flows (Detail) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Jun. 28, 2014	Jun. 29, 2013
OPERATING ACTIVITIES	'	'
Net cash provided by (used in) operating activities	$376.70	$415.80
INVESTING ACTIVITIES	'	'
Acquisition of businesses	0	-6.3
Payment of additional acquisition consideration	0	-16.8
Proceeds from sale of business, net of cash transferred	2.4	86.3
Purchase of property and equipment	-30.9	-41.1
Increase in equipment under customer usage agreements	-26.9	-31.9
Net sales (purchases) of insurance contracts	13.8	-4
Purchases of mutual funds	-29.7	0
Sales of mutual funds	22.4	0
Proceeds from sale of intellectual property	0	60
Purchase of cost-method equity investments	0	-3.6
Sale of a cost-method equity investment	0	2.1
Increase in other assets	-3	-4.6
Net cash (used in) provided by investing activities	-51.9	40.1
FINANCING ACTIVITIES	'	'
Repayment of long-term debt	-578.8	-48.8
Payment of debt issuance costs	-2.4	-7
Payment of contingent consideration	0	-42.4
Payment of deferred acquisition consideration	-5	-1.7
Net proceeds from issuance of common stock pursuant to employee stock plans	75.8	51.2
Excess tax benefit related to equity awards	5.2	5.4
Payment of minimum tax withholdings on net share settlements of equity awards	-9.2	-12
Intercompany dividend	'	0
Net cash used in financing activities	-514.4	-55.3
Effect of exchange rate changes on cash and cash equivalents	-0.4	-2.6
Net (decrease) increase in cash and cash equivalents	-190	398
Cash and cash equivalents, beginning of period	822.5	560.4
Cash and cash equivalents, end of period	632.5	958.4
Eliminations [Member]	'	'
OPERATING ACTIVITIES	'	'
Net cash provided by (used in) operating activities	0	0
INVESTING ACTIVITIES	'	'
Acquisition of businesses	'	0
Payment of additional acquisition consideration	'	0
Proceeds from sale of business, net of cash transferred	0	0
Purchase of property and equipment	0	0
Increase in equipment under customer usage agreements	0	0
Net sales (purchases) of insurance contracts	0	0
Purchases of mutual funds	0	'
Sales of mutual funds	0	'
Proceeds from sale of intellectual property	'	0
Purchase of cost-method equity investments	'	0
Sale of a cost-method equity investment	'	0
Increase in other assets	0	0
Net cash (used in) provided by investing activities	0	0
FINANCING ACTIVITIES	'	'
Repayment of long-term debt	0	0
Payment of debt issuance costs	0	0
Payment of contingent consideration	'	0
Payment of deferred acquisition consideration	0	0
Net proceeds from issuance of common stock pursuant to employee stock plans	0	0
Excess tax benefit related to equity awards	0	0
Payment of minimum tax withholdings on net share settlements of equity awards	0	0
Intercompany dividend	'	0
Net cash used in financing activities	0	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net (decrease) increase in cash and cash equivalents	0	0
Cash and cash equivalents, beginning of period	0	0
Cash and cash equivalents, end of period	0	0
Parent/Issuer [Member]	'	'
OPERATING ACTIVITIES	'	'
Net cash provided by (used in) operating activities	412.6	218.4
INVESTING ACTIVITIES	'	'
Acquisition of businesses	'	-6.1
Payment of additional acquisition consideration	'	-16.8
Proceeds from sale of business, net of cash transferred	0	0
Purchase of property and equipment	-9.4	-13.1
Increase in equipment under customer usage agreements	-0.5	-0.5
Net sales (purchases) of insurance contracts	13.8	-4
Purchases of mutual funds	-29.7	'
Sales of mutual funds	22.4	'
Proceeds from sale of intellectual property	'	0
Purchase of cost-method equity investments	'	-3.4
Sale of a cost-method equity investment	'	2.1
Increase in other assets	-1	-2.1
Net cash (used in) provided by investing activities	-4.4	-43.9
FINANCING ACTIVITIES	'	'
Repayment of long-term debt	-578.8	-48.8
Payment of debt issuance costs	-2.4	-7
Payment of contingent consideration	'	-42.4
Payment of deferred acquisition consideration	-5	-1.7
Net proceeds from issuance of common stock pursuant to employee stock plans	75.8	51.2
Excess tax benefit related to equity awards	5.2	5.4
Payment of minimum tax withholdings on net share settlements of equity awards	-9.2	-12
Intercompany dividend	'	175
Net cash used in financing activities	-514.4	-55.3
Effect of exchange rate changes on cash and cash equivalents	0	0
Net (decrease) increase in cash and cash equivalents	-106.2	119.2
Cash and cash equivalents, beginning of period	321.6	210
Cash and cash equivalents, end of period	215.4	329.2
Guarantor Subsidiaries [Member]	'	'
OPERATING ACTIVITIES	'	'
Net cash provided by (used in) operating activities	-81.1	146.4
INVESTING ACTIVITIES	'	'
Acquisition of businesses	'	0
Payment of additional acquisition consideration	'	0
Proceeds from sale of business, net of cash transferred	0	84.8
Purchase of property and equipment	-15.3	-19.7
Increase in equipment under customer usage agreements	-15.8	-18.8
Net sales (purchases) of insurance contracts	0	0
Purchases of mutual funds	0	'
Sales of mutual funds	0	'
Proceeds from sale of intellectual property	'	60
Purchase of cost-method equity investments	'	-0.2
Sale of a cost-method equity investment	'	0
Increase in other assets	-3	-2.1
Net cash (used in) provided by investing activities	-34.1	104
FINANCING ACTIVITIES	'	'
Repayment of long-term debt	0	0
Payment of debt issuance costs	0	0
Payment of contingent consideration	'	0
Payment of deferred acquisition consideration	0	0
Net proceeds from issuance of common stock pursuant to employee stock plans	0	0
Excess tax benefit related to equity awards	0	0
Payment of minimum tax withholdings on net share settlements of equity awards	0	0
Intercompany dividend	'	-175
Net cash used in financing activities	0	0
Effect of exchange rate changes on cash and cash equivalents	0.4	-3
Net (decrease) increase in cash and cash equivalents	-114.8	247.4
Cash and cash equivalents, beginning of period	387.4	269.4
Cash and cash equivalents, end of period	272.6	516.8
Non-Guarantor Subsidiaries [Member]	'	'
OPERATING ACTIVITIES	'	'
Net cash provided by (used in) operating activities	45.2	51
INVESTING ACTIVITIES	'	'
Acquisition of businesses	'	-0.2
Payment of additional acquisition consideration	'	0
Proceeds from sale of business, net of cash transferred	2.4	1.5
Purchase of property and equipment	-6.2	-8.3
Increase in equipment under customer usage agreements	-10.6	-12.6
Net sales (purchases) of insurance contracts	0	0
Purchases of mutual funds	0	'
Sales of mutual funds	0	'
Proceeds from sale of intellectual property	'	0
Purchase of cost-method equity investments	'	0
Sale of a cost-method equity investment	'	0
Increase in other assets	1	-0.4
Net cash (used in) provided by investing activities	-13.4	-20
FINANCING ACTIVITIES	'	'
Repayment of long-term debt	0	0
Payment of debt issuance costs	0	0
Payment of contingent consideration	'	0
Payment of deferred acquisition consideration	0	0
Net proceeds from issuance of common stock pursuant to employee stock plans	0	0
Excess tax benefit related to equity awards	0	0
Payment of minimum tax withholdings on net share settlements of equity awards	0	0
Intercompany dividend	'	0
Net cash used in financing activities	0	0
Effect of exchange rate changes on cash and cash equivalents	-0.8	0.4
Net (decrease) increase in cash and cash equivalents	31	31.4
Cash and cash equivalents, beginning of period	113.5	81
Cash and cash equivalents, end of period	$144.50	$112.40